{
  "migration": {
    "timestamp": "2025-06-04T16:58:35.677Z",
    "mode": "live",
    "sourceDirectory": "../",
    "sanityProject": "aonp1fhb",
    "sanityDataset": "production"
  },
  "summary": {
    "totalFilesProcessed": 0,
    "totalDocumentsCreated": 12,
    "totalAssetsUploaded": 179,
    "totalFailures": 3,
    "totalUrlMappings": 11,
    "dataLoss": "potential"
  },
  "documents": [
    {
      "_id": "main-profile",
      "_type": "profile",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-fQJTl4FpPCqenn4L6NpST",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-DLwDiYx_QiYzxbE4CM_Gl",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-_3irlGZ1APnuumi1Ov6FX",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-oljUbzaZ4mtUv-Yowo9cz",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-atQXPKtM5nh_44FeaFbfB",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research--bQsrIkurMDc9xbk0kQdI",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-9-8Pjem9Z1MCyr0XxKfIf",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-aepOOvQLx8k5BFrZKl1Rq",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-lxPwpB2g2PUWNLhxvVsfA",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "research-eS_9GObqx2bDD5KS6d3O6",
      "_type": "researchProject",
      "title": "Ishan Perera"
    },
    {
      "_id": "nrs-scale-demo",
      "_type": "project",
      "title": "NRS Scale Demo"
    }
  ],
  "assets": [
    {
      "path": "assets/img/apple-touch-icon.png",
      "sanityId": "image-e5c27193981ab430e3711fbbba428ae981ac5def-400x400-png"
    },
    {
      "path": "assets/img/favicon.png",
      "sanityId": "image-e5c27193981ab430e3711fbbba428ae981ac5def-400x400-png"
    },
    {
      "path": "assets/img/hero-bg2.JPEG",
      "sanityId": "image-c4528d23a67dd31021a81534e901b5a70fd8a3ba-4692x3178-jpg"
    },
    {
      "path": "assets/img/profile-img2.jpg",
      "sanityId": "image-4826edc573c678d7fdd540f90a1521af974bb68a-3024x4032-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-carrie.jpeg",
      "sanityId": "image-a03d029eecef74b4a105e8bbc82876ef9e1a774c-500x500-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-fred.jpeg",
      "sanityId": "image-998244b26426e3fb061008106cb64b8aee17e8fc-500x700-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-jeff.jpeg",
      "sanityId": "image-758490df64f230e34a10620eacc079675079a282-636x636-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-katz.jpeg",
      "sanityId": "image-9591ccd872b8d53e46b952c7d9029f6132471d2a-202x202-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-nikos.jpeg",
      "sanityId": "image-453c3321166586abc0d93d262b95c34ba5c7e8c5-449x449-jpg"
    },
    {
      "path": "assets/img/testimonials/testimonials-singh.jpg",
      "sanityId": "image-9a43780355a6393d5feac5cce2dac299efb9900c-480x600-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/@jest/reporters/assets/jest_logo.png",
      "sanityId": "image-73fcd0608275a990f0c8a743fc1cfe57674366ef-70x70-png"
    },
    {
      "path": "portfolio-frontend/node_modules/@lhci/cli/node_modules/mute-stream/coverage/lcov-report/sort-arrow-sprite.png",
      "sanityId": "image-7d887a09a1d329cb65d85327cc809ced7059b35f-7x27-png"
    },
    {
      "path": "portfolio-frontend/node_modules/@sanity/runtime-cli/dist/server/static/favicon-dark.svg",
      "sanityId": "image-b10d4cfac6e015f6587493835eed0159836eeede-32x32-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/@sanity/runtime-cli/dist/server/static/favicon.svg",
      "sanityId": "image-71e4e78813bb0f546b9ffc35812cdd2dce33c315-32x32-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/browserify-zlib/test/fixtures/person.jpg",
      "sanityId": "image-2bddb4313607801766e62dec5d800287f334a748-180x240-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/commitizen/logo/commitizen-logo-color.svg",
      "sanityId": "image-2270613c2448fef523324ed307cb58f663b56343-512x512-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/commitizen/logo/commitizen-logo-mono.svg",
      "sanityId": "image-06067ce3336f894e2b8a2b94b5898081f6563b19-512x512-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/date-fns/docs/logo.svg",
      "sanityId": "image-d100ef0c064169ecc59ca96ff03fbbcbd076a20f-32x26-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/date-fns/docs/logotype.svg",
      "sanityId": "image-12d3097267e91bbfc884cc5688d6219fd11c5e45-176x33-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/getos/imgs/logo.png",
      "sanityId": "image-34b48b79c0b523260711a950c1c53c0b4f727b5a-400x440-png"
    },
    {
      "path": "portfolio-frontend/node_modules/getos/imgs/logo.svg",
      "sanityId": "image-bb39b55fa57f4389e16dc2a01b22bf14783097f3-509x560-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/scss/brown-papersq.png",
      "sanityId": "image-3a1332ede3a75a3d24f60b6ed69035b72da5e182-987x35-png"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/scss/pojoaque.jpg",
      "sanityId": "image-c5fe6533b88b21f8d90d3d03954c6b29baa67791-140x140-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/scss/school-book.png",
      "sanityId": "image-711ec983c874e093bb89eb77afcbdf6741fa61ee-987x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/styles/brown-papersq.png",
      "sanityId": "image-3a1332ede3a75a3d24f60b6ed69035b72da5e182-987x35-png"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/styles/pojoaque.jpg",
      "sanityId": "image-c5fe6533b88b21f8d90d3d03954c6b29baa67791-140x140-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/highlight.js/styles/school-book.png",
      "sanityId": "image-711ec983c874e093bb89eb77afcbdf6741fa61ee-987x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/html-webpack-plugin-5/node_modules/renderkid/docs/images/bullets-1.png",
      "sanityId": "image-d81b77f56530c4395a928df26c3a7d64a076806d-728x116-png"
    },
    {
      "path": "portfolio-frontend/node_modules/html-webpack-plugin-5/node_modules/renderkid/docs/images/display.png",
      "sanityId": "image-ecfa1c1135e002099d607d982410bf1b8e3349dd-760x74-png"
    },
    {
      "path": "portfolio-frontend/node_modules/html-webpack-plugin-5/node_modules/renderkid/docs/images/usage.png",
      "sanityId": "image-ea4dbfdd4a4935754e217c123c5679f3bd9bfad3-760x118-png"
    },
    {
      "path": "portfolio-frontend/node_modules/istanbul-reports/lib/html/assets/favicon.png",
      "sanityId": "image-5ad26e9cc50a29dd96f8dfd7c3f1a50cce0b2539-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/istanbul-reports/lib/html/assets/sort-arrow-sprite.png",
      "sanityId": "image-da5c0ef467a330913336cd9b0da5f3c900af6c3e-7x27-png"
    },
    {
      "path": "portfolio-frontend/node_modules/istanbul-reports/lib/html-spa/assets/sort-arrow-sprite.png",
      "sanityId": "image-da5c0ef467a330913336cd9b0da5f3c900af6c3e-7x27-png"
    },
    {
      "path": "portfolio-frontend/node_modules/playwright-core/lib/server/chromium/appIcon.png",
      "sanityId": "image-12753725e3f214acff8e1fa1ce68574b3d1dc39b-400x400-png"
    },
    {
      "path": "portfolio-frontend/node_modules/playwright-core/lib/vite/recorder/playwright-logo.svg",
      "sanityId": "image-6a163ae94b0df23c01e41dddd064170a4c0a18e3-400x400-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/playwright-core/lib/vite/traceViewer/playwright-logo.svg",
      "sanityId": "image-6a163ae94b0df23c01e41dddd064170a4c0a18e3-400x400-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/polished/docs/assets/GitHub-Mark-Light-64px.png",
      "sanityId": "image-a0ef37636cdbcaeb772500419cc523677b8350bd-64x64-png"
    },
    {
      "path": "portfolio-frontend/node_modules/polished/docs/assets/logo.svg",
      "sanityId": "image-713c3c8c7b6adfa2d90aea27204a6231183af8cb-318x318-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/polished/docs/assets/meta.png",
      "sanityId": "image-3f510411e2b7f19d99a7bcc23a9d2eea784f32eb-1024x512-png"
    },
    {
      "path": "portfolio-frontend/node_modules/polished/docs/favicon.png",
      "sanityId": "image-b07cc52ba67b1d1b1e69c14deb33141b16329323-128x128-png"
    },
    {
      "path": "portfolio-frontend/node_modules/psl/browserstack-logo.svg",
      "sanityId": "image-ce56266030efa5233f6f84585232ee6f0284ed32-490x106-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/renderkid/docs/images/bullets-1.png",
      "sanityId": "image-d81b77f56530c4395a928df26c3a7d64a076806d-728x116-png"
    },
    {
      "path": "portfolio-frontend/node_modules/renderkid/docs/images/display.png",
      "sanityId": "image-ecfa1c1135e002099d607d982410bf1b8e3349dd-760x74-png"
    },
    {
      "path": "portfolio-frontend/node_modules/renderkid/docs/images/usage.png",
      "sanityId": "image-ea4dbfdd4a4935754e217c123c5679f3bd9bfad3-760x118-png"
    },
    {
      "path": "portfolio-frontend/node_modules/rxjs-exhaustmap-with-trailing/marbles.svg",
      "sanityId": "image-f30bd47b78618d31dbad3cb43471c35b363c4db2-550x260-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/src/_internal/cli/actions/media/test/fixtures/test-media-library-directory/images/2167dbd2135fce8298cc1448eeb512ed60b3224b-5472x3648.jpg",
      "sanityId": "image-1ce350b91b29ae7181e0d21d9f2f43f296a7fa2b-5472x3648-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/src/_internal/cli/actions/media/test/fixtures/test-media-library-directory/images/a2e6ee830963242992e07afd2773b02a65821939-166x112.jpg",
      "sanityId": "image-70ca3916b4dd69a530fa82585249be5e0842b6fe-166x112-jpg"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/static/favicons/apple-touch-icon.png",
      "sanityId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/static/favicons/favicon-192.png",
      "sanityId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/static/favicons/favicon-512.png",
      "sanityId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/static/favicons/favicon-96.png",
      "sanityId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png"
    },
    {
      "path": "portfolio-frontend/node_modules/sanity/static/favicons/favicon.svg",
      "sanityId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/application_xp.png",
      "sanityId": "image-09b6b09a8f7ee19dc0ff67f430b1856ea8f1602e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/application_xp_terminal.png",
      "sanityId": "image-5000245ec6c0156e78d26306e13081ae5d395136-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/box.png",
      "sanityId": "image-63764927f0df180fffe0163ef7b5672598c24a17-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/cd.png",
      "sanityId": "image-0aa0148dc5bdce78bb30330a489b5ec7ecbbfd66-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/controller.png",
      "sanityId": "image-2e2b34758d67aeb19b454bf5fbb43f4e9e3ebe62-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/drive.png",
      "sanityId": "image-aee9f81efbb34149deb0c23f29a67c5419a54dc0-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/film.png",
      "sanityId": "image-3811ee746f69176ff8c7b610ae5c4ce80e0ec50b-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/folder.png",
      "sanityId": "image-cc7aa40c08dbbc47e7faf9fbad7a3be2e9abc6b3-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/font.png",
      "sanityId": "image-3abea4e9b37b10b008221c8c69af9f32748f33c4-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/image.png",
      "sanityId": "image-d7d5903cca7649f70e98e5d8ed27df5ae1095883-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/map.png",
      "sanityId": "image-1efd12e6aa866c97ea8c311d428b26dcdd9ff7a7-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page.png",
      "sanityId": "image-b32cc1f2cfc3ca5dd2e81c15a04afb194ca00ee2-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_add.png",
      "sanityId": "image-18a2b3df06820d185cfd259bd44561bd9b24d88c-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_attach.png",
      "sanityId": "image-45dc77b8c52ac588c045ea644cc2920a3569bd21-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_code.png",
      "sanityId": "image-a55f11f670f848b13e33bf726541d99225b28919-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_copy.png",
      "sanityId": "image-c10bfc3288ecb1370d21d97e2906a950e2b25f84-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_delete.png",
      "sanityId": "image-201689b7e328b8008ea41f6f2c66cdae0cea6e85-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_edit.png",
      "sanityId": "image-e25fb883611d467ce7ad9c4dc2ea76c733b0b926-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_error.png",
      "sanityId": "image-d22e019c4c17ed7a3e6f3479b63f9b3fe01a932b-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_excel.png",
      "sanityId": "image-3e9262dfb6db0d05b84812dbc6479931b18ba45d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_find.png",
      "sanityId": "image-c7ba350905b088e21e79a3d4568d7ad3cf0bcff2-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_gear.png",
      "sanityId": "image-730b9918a61562197692d7462cbd9b87ad8cec4d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_go.png",
      "sanityId": "image-ca010fb7c1f97831e6f41688ae9786b6daaeb679-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_green.png",
      "sanityId": "image-c340ced6de08f750f4a3cfcb6aa15f86d8802af8-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_key.png",
      "sanityId": "image-5c8d42667f97583f600444b62cdd9ddbab48cfc4-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_lightning.png",
      "sanityId": "image-8f643f1aeb945be680cf94c7c6093121bb39e868-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_link.png",
      "sanityId": "image-558e9c4cd06f019952ef88c74c9c92b31eb58e0e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_paintbrush.png",
      "sanityId": "image-b54b455849bee534bc0e378003e607f8e2410370-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_paste.png",
      "sanityId": "image-e7a94cba7a91797fa573c8a9f53eac57ef25b2f3-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_red.png",
      "sanityId": "image-96beb9fc1ee6087a51e336d19cfba2c82f5dfbdb-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_refresh.png",
      "sanityId": "image-d8ce1a7fabefacf71cb344d37b1925663b2693d7-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_save.png",
      "sanityId": "image-a5dcc920f81b42eddc363d7dd605630924ea7124-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white.png",
      "sanityId": "image-d17b7c9738f6e92712f67ef934149d7be6dd5e2e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_acrobat.png",
      "sanityId": "image-0cd7923476a98f84137b91c68e7488398770de57-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_actionscript.png",
      "sanityId": "image-d0914bdac7edbf36e5fc01de9359323ab9764fdf-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_add.png",
      "sanityId": "image-00b832cabb6158cd7b180d588fc82c72ecc6e429-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_c.png",
      "sanityId": "image-0893860ee2000170e2dc07db65730bd3e4060876-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_camera.png",
      "sanityId": "image-a028c0d5ffd6524d4156cbbaceba138a72b3c2f0-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_cd.png",
      "sanityId": "image-a1240997dbaa141c6d4500205ec4df45ab91400d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_code.png",
      "sanityId": "image-e17a9696a9d8344f115062bda45f7d65e7d0b9a9-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_code_red.png",
      "sanityId": "image-59fa04c7871eb560c337377cc87f81a5daca741f-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_coldfusion.png",
      "sanityId": "image-3a629ff0d648be597e291b7cde19a585728f8aba-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_compressed.png",
      "sanityId": "image-8ab0554f5fbb9d036c1af9223c9de9f54359cd1b-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_copy.png",
      "sanityId": "image-3a6e4545d7cf09c1b4c5a31b865e4af3a428e2ca-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_cplusplus.png",
      "sanityId": "image-11c8b008bf2f4516bb57e73512d738d8b3122a46-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_csharp.png",
      "sanityId": "image-14af06292fa9ca1bbe7ad48539f0c87903ef8313-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_cup.png",
      "sanityId": "image-a33539d95656790d1798ca077a39d00b41e61bfb-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_database.png",
      "sanityId": "image-c7ce83f920d97c0da50a6173d48874a85240f10f-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_delete.png",
      "sanityId": "image-67b1a6a400d64cd380cb4e1ebe98747b4d0e6d2c-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_dvd.png",
      "sanityId": "image-cc7dbe073e98c1e23abce12c0f4a2efac66cde0e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_edit.png",
      "sanityId": "image-31ccb1b272ca4499219c8759be04535779967ff6-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_error.png",
      "sanityId": "image-db02f178893789620b8e8eb608ebcfa3b60ff91c-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_excel.png",
      "sanityId": "image-fb427b4a4eb8bd117865733f63641250804bd91d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_find.png",
      "sanityId": "image-fb3e3255360ec2b143d74989613416be8cda877f-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_flash.png",
      "sanityId": "image-55f2d09dc2b5d9260f8a2dc148d9cb91518d0142-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_freehand.png",
      "sanityId": "image-266873e8ecfc5d68d71ad4554973179a1670dc28-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_gear.png",
      "sanityId": "image-1e74b4e0c258d140b71e2cd728b22ceb5dacbfce-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_get.png",
      "sanityId": "image-3ae44c77d6fc9e97414e91411f89300383e6133f-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_go.png",
      "sanityId": "image-5dbd5a560abb4af41b4a5ffe9ec393d80a5107e6-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_h.png",
      "sanityId": "image-c6fc8c3063d341565f5382549090a11790f3cd2b-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_horizontal.png",
      "sanityId": "image-5419dcbf9b64112f1d2006d53c2d969865b0c224-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_key.png",
      "sanityId": "image-ecdac7afae03710d3628d11e32f55060cca95b5d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_lightning.png",
      "sanityId": "image-2f018f3729372e062d3760a5b749005248045c2c-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_link.png",
      "sanityId": "image-f22c61e9ada80109224d022f10535dbc4effea78-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_magnify.png",
      "sanityId": "image-b03a9c2341f60720147bfd8ca96bc5512668f358-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_medal.png",
      "sanityId": "image-de29ca4382860c7414aeaa51d9124a233a061d75-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_office.png",
      "sanityId": "image-70cbf2982037bb1e21a56056ce77c9d34bcd477b-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_paint.png",
      "sanityId": "image-b250b6b841117965cea6b5183fe07a4606e2e4a5-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_paintbrush.png",
      "sanityId": "image-41488d81b67a2f9f021172de2219a72e35efddeb-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_paste.png",
      "sanityId": "image-9dbc22ea5a3801d6be96b95b46cf604d9ceacfa8-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_php.png",
      "sanityId": "image-8579034cffc0189037f12d8ceb8148dedab460ff-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_picture.png",
      "sanityId": "image-1c3f9b0c810c535843390d830bcff9a34a74033c-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_powerpoint.png",
      "sanityId": "image-05354cf216e48c824228a493861854a30b4b6aec-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_put.png",
      "sanityId": "image-ddbd58de59ea6d9c90eecd3819cc080630da6020-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_ruby.png",
      "sanityId": "image-ea70b65309de56cfad7f238b6fc26d8d7b44842e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_stack.png",
      "sanityId": "image-3bfdcd25c05458c03b1eb108852f0c3181ad77af-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_star.png",
      "sanityId": "image-69ce9ae28747d68c9b7a74efcaaee4dba133f3ea-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_swoosh.png",
      "sanityId": "image-bb277aab40b503c30a5b808ed23660c5485e076e-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_text.png",
      "sanityId": "image-efcd01b427aba05a478f9392edb5fd0a5a945290-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_text_width.png",
      "sanityId": "image-21f1befec1a0dcb4bd31dd020c4bb5434e1c7eef-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_tux.png",
      "sanityId": "image-070022b187bc7fac5cef9e0bab35b2870b0f1ff7-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_vector.png",
      "sanityId": "image-a432dc22717910f867ace57d2eab830b438c7726-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_visualstudio.png",
      "sanityId": "image-1f5ddf9fb0bc88ef4049a6933ee2b900dcd55d42-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_width.png",
      "sanityId": "image-7e885b8783eb81748b6e75453c730405e85f13ca-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_word.png",
      "sanityId": "image-677955dc21dcdab66dbe49a1e99ce38ead3a1927-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_world.png",
      "sanityId": "image-055e159e867506d297434a808bdc106b5515daab-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_wrench.png",
      "sanityId": "image-24201cbc48eb364173de76126c784dc54795e684-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_white_zip.png",
      "sanityId": "image-ce94ec8ec25eedd880bc1567540dc513dd5b181d-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_word.png",
      "sanityId": "image-6e23368579eb66ecfe22cda873d65babcfc29eb3-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/serve-index/public/icons/page_world.png",
      "sanityId": "image-7896e84500c0f4e060e609ae0a590f515dd4eebd-16x16-png"
    },
    {
      "path": "portfolio-frontend/node_modules/speed-measure-webpack-plugin/logo.svg",
      "sanityId": "image-b792007d07410aaa79653d775326e224d8c5e138-112x127-svg"
    },
    {
      "path": "portfolio-frontend/node_modules/speed-measure-webpack-plugin/preview.png",
      "sanityId": "image-0f9d615bc1eeb7505d1e36b5eda21e45cabcfe29-400x421-png"
    },
    {
      "path": "portfolio-frontend/node_modules/undici/docs/assets/lifecycle-diagram.png",
      "sanityId": "image-7fe9fdeb6222037aeb700bc5de3477ffbca9b8bc-789x658-png"
    },
    {
      "path": "portfolio-frontend/public/file.svg",
      "sanityId": "image-fb380eeffe87d50b597383664c02982964d0d28c-16x16-svg"
    },
    {
      "path": "portfolio-frontend/public/globe.svg",
      "sanityId": "image-2eba23b01a46733bb8423e6d38ebf5f7e95abec5-16x16-svg"
    },
    {
      "path": "portfolio-frontend/public/next.svg",
      "sanityId": "image-3f3e95622612b989c5bd6a03299a308c6f3c7e6b-394x80-svg"
    },
    {
      "path": "portfolio-frontend/public/vercel.svg",
      "sanityId": "image-cebb8852d58c8886be3e9051a26957f42bb82f1a-1155x1000-svg"
    },
    {
      "path": "portfolio-frontend/public/window.svg",
      "sanityId": "image-54c48e0daa6caa317fe1b4c419007fd93e948db9-16x16-svg"
    },
    {
      "path": "sanity/dist/static/apple-touch-icon.png",
      "sanityId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png"
    },
    {
      "path": "sanity/dist/static/favicon-192.png",
      "sanityId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png"
    },
    {
      "path": "sanity/dist/static/favicon-512.png",
      "sanityId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png"
    },
    {
      "path": "sanity/dist/static/favicon-96.png",
      "sanityId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png"
    },
    {
      "path": "sanity/dist/static/favicon.svg",
      "sanityId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg"
    },
    {
      "path": "sanity/node_modules/@sanity/runtime-cli/dist/server/static/favicon-dark.svg",
      "sanityId": "image-b10d4cfac6e015f6587493835eed0159836eeede-32x32-svg"
    },
    {
      "path": "sanity/node_modules/@sanity/runtime-cli/dist/server/static/favicon.svg",
      "sanityId": "image-71e4e78813bb0f546b9ffc35812cdd2dce33c315-32x32-svg"
    },
    {
      "path": "sanity/node_modules/browserify-zlib/test/fixtures/person.jpg",
      "sanityId": "image-2bddb4313607801766e62dec5d800287f334a748-180x240-jpg"
    },
    {
      "path": "sanity/node_modules/date-fns/docs/logo.svg",
      "sanityId": "image-d100ef0c064169ecc59ca96ff03fbbcbd076a20f-32x26-svg"
    },
    {
      "path": "sanity/node_modules/date-fns/docs/logotype.svg",
      "sanityId": "image-12d3097267e91bbfc884cc5688d6219fd11c5e45-176x33-svg"
    },
    {
      "path": "sanity/node_modules/polished/docs/assets/GitHub-Mark-Light-64px.png",
      "sanityId": "image-a0ef37636cdbcaeb772500419cc523677b8350bd-64x64-png"
    },
    {
      "path": "sanity/node_modules/polished/docs/assets/logo.svg",
      "sanityId": "image-713c3c8c7b6adfa2d90aea27204a6231183af8cb-318x318-svg"
    },
    {
      "path": "sanity/node_modules/polished/docs/assets/meta.png",
      "sanityId": "image-3f510411e2b7f19d99a7bcc23a9d2eea784f32eb-1024x512-png"
    },
    {
      "path": "sanity/node_modules/polished/docs/favicon.png",
      "sanityId": "image-b07cc52ba67b1d1b1e69c14deb33141b16329323-128x128-png"
    },
    {
      "path": "sanity/node_modules/psl/browserstack-logo.svg",
      "sanityId": "image-ce56266030efa5233f6f84585232ee6f0284ed32-490x106-svg"
    },
    {
      "path": "sanity/node_modules/rxjs-exhaustmap-with-trailing/marbles.svg",
      "sanityId": "image-f30bd47b78618d31dbad3cb43471c35b363c4db2-550x260-svg"
    },
    {
      "path": "sanity/node_modules/sanity/src/_internal/cli/actions/media/test/fixtures/test-media-library-directory/images/2167dbd2135fce8298cc1448eeb512ed60b3224b-5472x3648.jpg",
      "sanityId": "image-1ce350b91b29ae7181e0d21d9f2f43f296a7fa2b-5472x3648-jpg"
    },
    {
      "path": "sanity/node_modules/sanity/src/_internal/cli/actions/media/test/fixtures/test-media-library-directory/images/a2e6ee830963242992e07afd2773b02a65821939-166x112.jpg",
      "sanityId": "image-70ca3916b4dd69a530fa82585249be5e0842b6fe-166x112-jpg"
    },
    {
      "path": "sanity/node_modules/sanity/static/favicons/apple-touch-icon.png",
      "sanityId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png"
    },
    {
      "path": "sanity/node_modules/sanity/static/favicons/favicon-192.png",
      "sanityId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png"
    },
    {
      "path": "sanity/node_modules/sanity/static/favicons/favicon-512.png",
      "sanityId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png"
    },
    {
      "path": "sanity/node_modules/sanity/static/favicons/favicon-96.png",
      "sanityId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png"
    },
    {
      "path": "sanity/node_modules/sanity/static/favicons/favicon.svg",
      "sanityId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg"
    },
    {
      "path": "sanity/node_modules/undici/docs/assets/lifecycle-diagram.png",
      "sanityId": "image-7fe9fdeb6222037aeb700bc5de3477ffbca9b8bc-789x658-png"
    },
    {
      "path": "sanity-old/dist/static/apple-touch-icon.png",
      "sanityId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png"
    },
    {
      "path": "sanity-old/dist/static/favicon-192.png",
      "sanityId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png"
    },
    {
      "path": "sanity-old/dist/static/favicon-512.png",
      "sanityId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png"
    },
    {
      "path": "sanity-old/dist/static/favicon-96.png",
      "sanityId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png"
    },
    {
      "path": "sanity-old/dist/static/favicon.svg",
      "sanityId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg"
    }
  ],
  "urlMappings": [
    {
      "oldUrl": "/airway_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-fQJTl4FpPCqenn4L6NpST"
    },
    {
      "oldUrl": "/chiari_project1.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-DLwDiYx_QiYzxbE4CM_Gl"
    },
    {
      "oldUrl": "/gbcurrent_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-_3irlGZ1APnuumi1Ov6FX"
    },
    {
      "oldUrl": "/gbnovel_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-oljUbzaZ4mtUv-Yowo9cz"
    },
    {
      "oldUrl": "/ipf_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-atQXPKtM5nh_44FeaFbfB"
    },
    {
      "oldUrl": "/ndm_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research--bQsrIkurMDc9xbk0kQdI"
    },
    {
      "oldUrl": "/pca_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-9-8Pjem9Z1MCyr0XxKfIf"
    },
    {
      "oldUrl": "/revive_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-aepOOvQLx8k5BFrZKl1Rq"
    },
    {
      "oldUrl": "/toa_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-lxPwpB2g2PUWNLhxvVsfA"
    },
    {
      "oldUrl": "/vr_project.html",
      "newUrl": "/projects/ishan-perera",
      "_id": "research-eS_9GObqx2bDD5KS6d3O6"
    },
    {
      "oldUrl": "/portfolio_scripts.html",
      "newUrl": "/projects/nrs-scale-demo",
      "_id": "nrs-scale-demo"
    }
  ],
  "failures": [
    {
      "file": "assets/vendor/boxicons/fonts/boxicons.svg",
      "error": "Asset upload failed after 3 attempts: Bad Request - Invalid image, could not read metadata",
      "timestamp": "2025-06-04T16:55:31.552Z"
    },
    {
      "file": "portfolio-frontend/public/android-chrome-192x192.png",
      "error": "Asset upload failed after 3 attempts: Bad Request - Invalid image, could not read metadata",
      "timestamp": "2025-06-04T16:57:41.668Z"
    },
    {
      "file": "portfolio-frontend/public/android-chrome-512x512.png",
      "error": "Asset upload failed after 3 attempts: Bad Request - Invalid image, could not read metadata",
      "timestamp": "2025-06-04T16:57:45.097Z"
    }
  ],
  "rollbackData": [
    {
      "operation": "create",
      "documentId": "image-e5c27193981ab430e3711fbbba428ae981ac5def-400x400-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-e5c27193981ab430e3711fbbba428ae981ac5def-400x400-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c4528d23a67dd31021a81534e901b5a70fd8a3ba-4692x3178-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-4826edc573c678d7fdd540f90a1521af974bb68a-3024x4032-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a03d029eecef74b4a105e8bbc82876ef9e1a774c-500x500-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-998244b26426e3fb061008106cb64b8aee17e8fc-500x700-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-758490df64f230e34a10620eacc079675079a282-636x636-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-9591ccd872b8d53e46b952c7d9029f6132471d2a-202x202-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-453c3321166586abc0d93d262b95c34ba5c7e8c5-449x449-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-9a43780355a6393d5feac5cce2dac299efb9900c-480x600-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-73fcd0608275a990f0c8a743fc1cfe57674366ef-70x70-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7d887a09a1d329cb65d85327cc809ced7059b35f-7x27-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b10d4cfac6e015f6587493835eed0159836eeede-32x32-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-71e4e78813bb0f546b9ffc35812cdd2dce33c315-32x32-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2bddb4313607801766e62dec5d800287f334a748-180x240-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2270613c2448fef523324ed307cb58f663b56343-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-06067ce3336f894e2b8a2b94b5898081f6563b19-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d100ef0c064169ecc59ca96ff03fbbcbd076a20f-32x26-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-12d3097267e91bbfc884cc5688d6219fd11c5e45-176x33-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-34b48b79c0b523260711a950c1c53c0b4f727b5a-400x440-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-bb39b55fa57f4389e16dc2a01b22bf14783097f3-509x560-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3a1332ede3a75a3d24f60b6ed69035b72da5e182-987x35-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c5fe6533b88b21f8d90d3d03954c6b29baa67791-140x140-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-711ec983c874e093bb89eb77afcbdf6741fa61ee-987x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3a1332ede3a75a3d24f60b6ed69035b72da5e182-987x35-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c5fe6533b88b21f8d90d3d03954c6b29baa67791-140x140-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-711ec983c874e093bb89eb77afcbdf6741fa61ee-987x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d81b77f56530c4395a928df26c3a7d64a076806d-728x116-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ecfa1c1135e002099d607d982410bf1b8e3349dd-760x74-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ea4dbfdd4a4935754e217c123c5679f3bd9bfad3-760x118-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-5ad26e9cc50a29dd96f8dfd7c3f1a50cce0b2539-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-da5c0ef467a330913336cd9b0da5f3c900af6c3e-7x27-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-da5c0ef467a330913336cd9b0da5f3c900af6c3e-7x27-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-12753725e3f214acff8e1fa1ce68574b3d1dc39b-400x400-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-6a163ae94b0df23c01e41dddd064170a4c0a18e3-400x400-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-6a163ae94b0df23c01e41dddd064170a4c0a18e3-400x400-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a0ef37636cdbcaeb772500419cc523677b8350bd-64x64-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-713c3c8c7b6adfa2d90aea27204a6231183af8cb-318x318-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3f510411e2b7f19d99a7bcc23a9d2eea784f32eb-1024x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b07cc52ba67b1d1b1e69c14deb33141b16329323-128x128-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ce56266030efa5233f6f84585232ee6f0284ed32-490x106-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d81b77f56530c4395a928df26c3a7d64a076806d-728x116-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ecfa1c1135e002099d607d982410bf1b8e3349dd-760x74-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ea4dbfdd4a4935754e217c123c5679f3bd9bfad3-760x118-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-f30bd47b78618d31dbad3cb43471c35b363c4db2-550x260-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1ce350b91b29ae7181e0d21d9f2f43f296a7fa2b-5472x3648-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-70ca3916b4dd69a530fa82585249be5e0842b6fe-166x112-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-09b6b09a8f7ee19dc0ff67f430b1856ea8f1602e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-5000245ec6c0156e78d26306e13081ae5d395136-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-63764927f0df180fffe0163ef7b5672598c24a17-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-0aa0148dc5bdce78bb30330a489b5ec7ecbbfd66-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2e2b34758d67aeb19b454bf5fbb43f4e9e3ebe62-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-aee9f81efbb34149deb0c23f29a67c5419a54dc0-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3811ee746f69176ff8c7b610ae5c4ce80e0ec50b-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cc7aa40c08dbbc47e7faf9fbad7a3be2e9abc6b3-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3abea4e9b37b10b008221c8c69af9f32748f33c4-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d7d5903cca7649f70e98e5d8ed27df5ae1095883-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1efd12e6aa866c97ea8c311d428b26dcdd9ff7a7-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b32cc1f2cfc3ca5dd2e81c15a04afb194ca00ee2-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-18a2b3df06820d185cfd259bd44561bd9b24d88c-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-45dc77b8c52ac588c045ea644cc2920a3569bd21-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a55f11f670f848b13e33bf726541d99225b28919-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c10bfc3288ecb1370d21d97e2906a950e2b25f84-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-201689b7e328b8008ea41f6f2c66cdae0cea6e85-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-e25fb883611d467ce7ad9c4dc2ea76c733b0b926-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d22e019c4c17ed7a3e6f3479b63f9b3fe01a932b-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3e9262dfb6db0d05b84812dbc6479931b18ba45d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c7ba350905b088e21e79a3d4568d7ad3cf0bcff2-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-730b9918a61562197692d7462cbd9b87ad8cec4d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ca010fb7c1f97831e6f41688ae9786b6daaeb679-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c340ced6de08f750f4a3cfcb6aa15f86d8802af8-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-5c8d42667f97583f600444b62cdd9ddbab48cfc4-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-8f643f1aeb945be680cf94c7c6093121bb39e868-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-558e9c4cd06f019952ef88c74c9c92b31eb58e0e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b54b455849bee534bc0e378003e607f8e2410370-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-e7a94cba7a91797fa573c8a9f53eac57ef25b2f3-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-96beb9fc1ee6087a51e336d19cfba2c82f5dfbdb-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d8ce1a7fabefacf71cb344d37b1925663b2693d7-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a5dcc920f81b42eddc363d7dd605630924ea7124-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d17b7c9738f6e92712f67ef934149d7be6dd5e2e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-0cd7923476a98f84137b91c68e7488398770de57-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d0914bdac7edbf36e5fc01de9359323ab9764fdf-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-00b832cabb6158cd7b180d588fc82c72ecc6e429-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-0893860ee2000170e2dc07db65730bd3e4060876-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a028c0d5ffd6524d4156cbbaceba138a72b3c2f0-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a1240997dbaa141c6d4500205ec4df45ab91400d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-e17a9696a9d8344f115062bda45f7d65e7d0b9a9-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-59fa04c7871eb560c337377cc87f81a5daca741f-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3a629ff0d648be597e291b7cde19a585728f8aba-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-8ab0554f5fbb9d036c1af9223c9de9f54359cd1b-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3a6e4545d7cf09c1b4c5a31b865e4af3a428e2ca-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-11c8b008bf2f4516bb57e73512d738d8b3122a46-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-14af06292fa9ca1bbe7ad48539f0c87903ef8313-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a33539d95656790d1798ca077a39d00b41e61bfb-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c7ce83f920d97c0da50a6173d48874a85240f10f-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-67b1a6a400d64cd380cb4e1ebe98747b4d0e6d2c-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cc7dbe073e98c1e23abce12c0f4a2efac66cde0e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-31ccb1b272ca4499219c8759be04535779967ff6-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-db02f178893789620b8e8eb608ebcfa3b60ff91c-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-fb427b4a4eb8bd117865733f63641250804bd91d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-fb3e3255360ec2b143d74989613416be8cda877f-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-55f2d09dc2b5d9260f8a2dc148d9cb91518d0142-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-266873e8ecfc5d68d71ad4554973179a1670dc28-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1e74b4e0c258d140b71e2cd728b22ceb5dacbfce-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3ae44c77d6fc9e97414e91411f89300383e6133f-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-5dbd5a560abb4af41b4a5ffe9ec393d80a5107e6-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-c6fc8c3063d341565f5382549090a11790f3cd2b-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-5419dcbf9b64112f1d2006d53c2d969865b0c224-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ecdac7afae03710d3628d11e32f55060cca95b5d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2f018f3729372e062d3760a5b749005248045c2c-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-f22c61e9ada80109224d022f10535dbc4effea78-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b03a9c2341f60720147bfd8ca96bc5512668f358-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-de29ca4382860c7414aeaa51d9124a233a061d75-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-70cbf2982037bb1e21a56056ce77c9d34bcd477b-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b250b6b841117965cea6b5183fe07a4606e2e4a5-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-41488d81b67a2f9f021172de2219a72e35efddeb-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-9dbc22ea5a3801d6be96b95b46cf604d9ceacfa8-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-8579034cffc0189037f12d8ceb8148dedab460ff-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1c3f9b0c810c535843390d830bcff9a34a74033c-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-05354cf216e48c824228a493861854a30b4b6aec-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ddbd58de59ea6d9c90eecd3819cc080630da6020-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ea70b65309de56cfad7f238b6fc26d8d7b44842e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3bfdcd25c05458c03b1eb108852f0c3181ad77af-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-69ce9ae28747d68c9b7a74efcaaee4dba133f3ea-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-bb277aab40b503c30a5b808ed23660c5485e076e-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-efcd01b427aba05a478f9392edb5fd0a5a945290-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-21f1befec1a0dcb4bd31dd020c4bb5434e1c7eef-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-070022b187bc7fac5cef9e0bab35b2870b0f1ff7-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a432dc22717910f867ace57d2eab830b438c7726-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1f5ddf9fb0bc88ef4049a6933ee2b900dcd55d42-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7e885b8783eb81748b6e75453c730405e85f13ca-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-677955dc21dcdab66dbe49a1e99ce38ead3a1927-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-055e159e867506d297434a808bdc106b5515daab-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-24201cbc48eb364173de76126c784dc54795e684-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ce94ec8ec25eedd880bc1567540dc513dd5b181d-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-6e23368579eb66ecfe22cda873d65babcfc29eb3-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7896e84500c0f4e060e609ae0a590f515dd4eebd-16x16-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b792007d07410aaa79653d775326e224d8c5e138-112x127-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-0f9d615bc1eeb7505d1e36b5eda21e45cabcfe29-400x421-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7fe9fdeb6222037aeb700bc5de3477ffbca9b8bc-789x658-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-fb380eeffe87d50b597383664c02982964d0d28c-16x16-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2eba23b01a46733bb8423e6d38ebf5f7e95abec5-16x16-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3f3e95622612b989c5bd6a03299a308c6f3c7e6b-394x80-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cebb8852d58c8886be3e9051a26957f42bb82f1a-1155x1000-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-54c48e0daa6caa317fe1b4c419007fd93e948db9-16x16-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b10d4cfac6e015f6587493835eed0159836eeede-32x32-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-71e4e78813bb0f546b9ffc35812cdd2dce33c315-32x32-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-2bddb4313607801766e62dec5d800287f334a748-180x240-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-d100ef0c064169ecc59ca96ff03fbbcbd076a20f-32x26-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-12d3097267e91bbfc884cc5688d6219fd11c5e45-176x33-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-a0ef37636cdbcaeb772500419cc523677b8350bd-64x64-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-713c3c8c7b6adfa2d90aea27204a6231183af8cb-318x318-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-3f510411e2b7f19d99a7bcc23a9d2eea784f32eb-1024x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-b07cc52ba67b1d1b1e69c14deb33141b16329323-128x128-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ce56266030efa5233f6f84585232ee6f0284ed32-490x106-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-f30bd47b78618d31dbad3cb43471c35b363c4db2-550x260-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-1ce350b91b29ae7181e0d21d9f2f43f296a7fa2b-5472x3648-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-70ca3916b4dd69a530fa82585249be5e0842b6fe-166x112-jpg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7fe9fdeb6222037aeb700bc5de3477ffbca9b8bc-789x658-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-cdb4f895c1ef6a177ab088727f13e22bc6d63024-180x180-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-eb08c55d811963d165dd82b8e117e1351d5fda65-192x192-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-ccb0b846acb26e75a97322d1ec4377ec5397c78f-512x512-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-7a7fa7ced404c1924b07a15b857fa92a0a48f718-96x96-png",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "image-14eeb6629b60a83024a6dfaf2c95ee95ac8879f1-512x512-svg",
      "data": {
        "_type": "sanity.imageAsset"
      }
    },
    {
      "operation": "create",
      "documentId": "main-profile",
      "data": {
        "_createdAt": "2025-06-04T16:58:19Z",
        "_id": "main-profile",
        "_rev": "0R95WGIfgjXsgEpFfwHh8B",
        "_type": "profile",
        "_updatedAt": "2025-06-04T16:58:19Z",
        "bio": "",
        "email": "",
        "heroBackground": {
          "_type": "image",
          "asset": {
            "_ref": "image-c4528d23a67dd31021a81534e901b5a70fd8a3ba-4692x3178-jpg",
            "_type": "reference"
          }
        },
        "location": "",
        "name": "Ishan Perera",
        "phone": "",
        "profileImage": {
          "_type": "image",
          "asset": {
            "_ref": "image-4826edc573c678d7fdd540f90a1521af974bb68a-3024x4032-jpg",
            "_type": "reference"
          }
        },
        "publishedAt": "2025-06-04T16:58:19.627Z",
        "socialLinks": [],
        "typedRoles": []
      }
    },
    {
      "operation": "create",
      "documentId": "research-fQJTl4FpPCqenn4L6NpST",
      "data": {
        "_createdAt": "2025-06-04T16:58:21Z",
        "_id": "research-fQJTl4FpPCqenn4L6NpST",
        "_rev": "jfcORSZ86cdtiqyuKTPvlX",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:21Z",
        "category": "original-research",
        "content": [
          {
            "_key": "Uiq-80wVEky_G1mettm7p",
            "_type": "block",
            "children": [
              {
                "_key": "8aZmTV3RypkBKK6QDGXIf",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "Rd4rYopjBGoCN7A-JmTCz",
            "_type": "block",
            "children": [
              {
                "_key": "cxX7lBYdn1v8FMH8LfEAj",
                "_type": "span",
                "marks": [],
                "text": "We are investigating the impact of a standardized training procedure with distinct\n                                focuses on Direct Laryngoscopy (DL), Indirect Video Laryngoscopy (IVL), and Direct Video\n                                Laryngoscopy (DVL) on trainees’ proficiency in performing the direct laryngoscopy\n                                technique with confidence. Previous studies have indicated that DL training, when\n                                compared to Video Laryngoscopy (VL) training, resulted in faster intubation times.\n                                Conversely, another study demonstrated that using a videolaryngoscope in both direct and\n                                indirect manners led to quicker DL times. This study aims to compare various training\n                                methods and assess performance outcomes based on metrics such as successful intubation,\n                                time to successful intubation, incidence of dental injury, and Numeric Rating Score\n                                (NRS) to gauge trainee self-perception and the trainee’s confidence level in performing\n                                intubation for future real-life scenarios. Our results indicate no statistical\n                                significance among modalities based on outcomes assessed through ANOVA and Tukey\n                                Contrast Tests. This suggests that observed differences lack statistical evidence for\n                                genuine distinction, potentially stemming from random variation.\n\n                                However, a nuanced analysis reveals that the effects of these modalities are not\n                                mutually exclusive, indicating a complex interplay of factors beyond modality selection.\n                                Upon stratifying data to exclude participants with prior intubation experience,\n                                video-based modalities exhibited a 100% positive difference in successful intubations,\n                                outperforming the Direct modality, which showed a 57% positive difference. Dental injury\n                                analysis yielded the greatest reduction in the DVL cohort. Additionally, DVL\n                                demonstrated the quickest time to intubation during post-assessment at 60 seconds, 21\n                                seconds faster than IVL and 29 seconds faster than DL. NRS of participant self\n                                perception demonstrated the smallest average difference from post to pre-assessment in\n                                the DVL cohort, with the greatest difference seen in the IVL group. NRS of participant\n                                confidence in performing intubation in a real-world intubation demonstrated the largest\n                                average difference within the DVL cohort from pre to post-assessment, with the smallest\n                                difference in the DL cohort. While statistical significance may elude the disparities\n                                among modalities, discerned patterns suggest a noteworthy efficacy of video-based\n                                approaches. These findings lay the groundwork for future studies to delve deeper into\n                                the role of video-based educational modalities in medical education and curriculum."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "_KP7Zy_9kZenz_KK1s2p0",
            "_type": "block",
            "children": [
              {
                "_key": "3uOmpzDRWYs3fBAYKkSD2",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "kvsXgCdYbnlwvKo92x3lo",
            "_type": "block",
            "children": [
              {
                "_key": "uWyD_McYp-_kpFMQRTfWo",
                "_type": "span",
                "marks": [],
                "text": "1. J. Breckwoldt, S. Klemstein, B. Brunne, L. Schnitzer, H. C. Mochmann, and H. R.\n                                Arntz, “Difficult prehospital endotracheal intubation – predisposing factors in a\n                                physician based EMS,” Resuscitation, vol. 82, no. 12, pp. 1519–1524, Dec. 2011, doi:\n                                10.1016/J.RESUSCITATION.2011.06.028.\n                                2. J. T. Mulcaster et al., “Laryngoscopic intubation: learning and performance,”\n                                Anesthesiology, vol. 98, no. 1, pp. 23–27, Jan. 2003, doi:\n                                10.1097/00000542-200301000-00007.\n                                3. M. L. Buis, I. M. Maissan, S. E. Hoeks, M. Klimek, and R. J. Stolker, “Defining the\n                                learning curve for endotracheal intubation using direct laryngoscopy: A systematic\n                                review,” Resuscitation, vol. 99, pp. 63–71, Feb. 2016, doi:\n                                10.1016/J.RESUSCITATION.2015.11.005.\n                                4. M. Gu, M. Lian, C. Gong, L. Chen, and S. Li, “The teaching order of using direct\n                                laryngoscopy first may improve the learning outcome of endotracheal incubation: A\n                                preliminary, randomized controlled trial,” Medicine, vol. 98, no. 21, May 2019, doi:\n                                10.1097/MD.0000000000015624.\n                                5. I. K. Yi, J. Hwang, S. K. Min, G. M. Lim, and Y. J. Chae, “Comparison of learning\n                                direct laryngoscopy using a McGrath videolaryngoscope as a direct versus indirect\n                                laryngoscope: a randomized controlled trial,” J Int Med Res, vol. 49, no. 5, 2021, doi:\n                                10.1177/03000605211016740.\n                                6. Y. Lim, T. J. Lim, and E. H. C. Liu, “Ease of intubation with the GlideScope or\n                                Macintosh laryngoscope by inexperienced operators in simulated difficult airways,” Can J\n                                Anaesth, vol. 51, no. 6, pp. 641–642, 2004, doi: 10.1007/BF03018415.\n                                7. T. J. Lim, Y. Lim, and E. H. C. Liu, “Evaluation of ease of intubation with the\n                                GlideScope or Macintosh laryngoscope by anaesthetists in simulated easy and difficult\n                                laryngoscopy,” Anaesthesia, vol. 60, no. 2, pp. 180–183, Feb. 2005, doi:\n                                10.1111/J.1365-2044.2004.04038.X.\n                                8. Vogel J, Stübinger S, Kaufmann M, Krastl G, Filippi A. Dental injuries resulting from\n                                tracheal intubation--a retrospective study. Dent Traumatol. 2009;25(1):73-77.\n                                doi:10.1111/j.1600-9657.2008.0067\n                                9. Owen H, Waddell-Smith I. Dental trauma associated with anaesthesia. Anaesth Intensive\n                                Care. 2000;28(2):133-145. doi:10.1177/0310057X0002800202 \n                                10. Neto JM, Teles AR, Barbosa J, Santos O. Teeth Damage during General Anesthesia. J\n                                Clin Med. 2023;12(16):5343. Published 2023 Aug 17. doi:10.3390/jcm12165343 \n                                11. Cook TM, Kelly FE. A national survey of videolaryngoscopy in the United Kingdom. Br\n                                J Anaesth. 2017;118(4):593-600. doi:10.1093/bja/aex052"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "We are investigating the impact of a standardized training procedure with distinct\n                                focuses on Direct Laryngoscopy (DL), Indirect Video Laryngoscopy (IVL), and Direct Video\n                                Laryngoscopy (DVL) on trainees’ proficiency in performing the di...",
        "publishedAt": "2025-06-04T16:58:20.938Z",
        "references": "1. J. Breckwoldt, S. Klemstein, B. Brunne, L. Schnitzer, H. C. Mochmann, and H. R.\n                                Arntz, “Difficult prehospital endotracheal intubation – predisposing factors in a\n                                physician based EMS,” Resuscitation, vol. 82, no. 12, pp. 1519–1524, Dec. 2011, doi:\n                                10.1016/J.RESUSCITATION.2011.06.028.\n                                2. J. T. Mulcaster et al., “Laryngoscopic intubation: learning and performance,”\n                                Anesthesiology, vol. 98, no. 1, pp. 23–27, Jan. 2003, doi:\n                                10.1097/00000542-200301000-00007.\n                                3. M. L. Buis, I. M. Maissan, S. E. Hoeks, M. Klimek, and R. J. Stolker, “Defining the\n                                learning curve for endotracheal intubation using direct laryngoscopy: A systematic\n                                review,” Resuscitation, vol. 99, pp. 63–71, Feb. 2016, doi:\n                                10.1016/J.RESUSCITATION.2015.11.005.\n                                4. M. Gu, M. Lian, C. Gong, L. Chen, and S. Li, “The teaching order of using direct\n                                laryngoscopy first may improve the learning outcome of endotracheal incubation: A\n                                preliminary, randomized controlled trial,” Medicine, vol. 98, no. 21, May 2019, doi:\n                                10.1097/MD.0000000000015624.\n                                5. I. K. Yi, J. Hwang, S. K. Min, G. M. Lim, and Y. J. Chae, “Comparison of learning\n                                direct laryngoscopy using a McGrath videolaryngoscope as a direct versus indirect\n                                laryngoscope: a randomized controlled trial,” J Int Med Res, vol. 49, no. 5, 2021, doi:\n                                10.1177/03000605211016740.\n                                6. Y. Lim, T. J. Lim, and E. H. C. Liu, “Ease of intubation with the GlideScope or\n                                Macintosh laryngoscope by inexperienced operators in simulated difficult airways,” Can J\n                                Anaesth, vol. 51, no. 6, pp. 641–642, 2004, doi: 10.1007/BF03018415.\n                                7. T. J. Lim, Y. Lim, and E. H. C. Liu, “Evaluation of ease of intubation with the\n                                GlideScope or Macintosh laryngoscope by anaesthetists in simulated easy and difficult\n                                laryngoscopy,” Anaesthesia, vol. 60, no. 2, pp. 180–183, Feb. 2005, doi:\n                                10.1111/J.1365-2044.2004.04038.X.\n                                8. Vogel J, Stübinger S, Kaufmann M, Krastl G, Filippi A. Dental injuries resulting from\n                                tracheal intubation--a retrospective study. Dent Traumatol. 2009;25(1):73-77.\n                                doi:10.1111/j.1600-9657.2008.0067\n                                9. Owen H, Waddell-Smith I. Dental trauma associated with anaesthesia. Anaesth Intensive\n                                Care. 2000;28(2):133-145. doi:10.1177/0310057X0002800202 \n                                10. Neto JM, Teles AR, Barbosa J, Santos O. Teeth Damage during General Anesthesia. J\n                                Clin Med. 2023;12(16):5343. Published 2023 Aug 17. doi:10.3390/jcm12165343 \n                                11. Cook TM, Kelly FE. A national survey of videolaryngoscopy in the United Kingdom. Br\n                                J Anaesth. 2017;118(4):593-600. doi:10.1093/bja/aex052",
        "researchers": [
          ": Moriarty",
          "S.",
          "Perera",
          "I.",
          "Sabbagh",
          "M.",
          "Yeckley",
          "M.",
          "Carpio",
          "P.",
          "Hoodfar",
          "A.",
          "Martin",
          "R.",
          "Daniels",
          "T.",
          "Edwards",
          "W.",
          "Rawlins II",
          "F."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-DLwDiYx_QiYzxbE4CM_Gl",
      "data": {
        "_createdAt": "2025-06-04T16:58:22Z",
        "_id": "research-DLwDiYx_QiYzxbE4CM_Gl",
        "_rev": "0R95WGIfgjXsgEpFfwHhMm",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:22Z",
        "category": "project",
        "content": [
          {
            "_key": "avscEiumeWIZ5TUUWxBfr",
            "_type": "block",
            "children": [
              {
                "_key": "krtU9pEv2UodU5GiGTgMT",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "P5Luiohh5Zq6o-UNEpd6D",
            "_type": "block",
            "children": [
              {
                "_key": "_faJfUu_7Od_9LjWC7fg1",
                "_type": "span",
                "marks": [],
                "text": "Introduction:\n                                Chiari malformation is typically defined as inferior descent of the cerebellar tonsils\n                                through the foramen magnum. Recent investigations attempting to characterize Chiari I\n                                malformation have included exhaustive collection of linear dimensions and angles in the\n                                midsagittal plane. The primary aim of this study is to describe midbrain and hindbrain\n                                shape using geometric morphometric techniques.\n\n                                Methods:\n                                Midsagittal MRI images from 94 Chiari-affected females and matched controls were\n                                landmarked using tpsDig264 (v.2.32) and tpsUtil64 (v.1.82). A total of 10 discrete and\n                                155 semilandmarks were placed on features of the midbrain and hindbrain. Generalized\n                                Procrustes superimposition and principal component analysis (PCA) were applied to the\n                                results using MorphoJ (v.1.07a). Independent-samples t-tests were applied to principal\n                                component (PC) scores to evaluate hypotheses related to configurational differences\n                                between groups. Past (v.4.03) and MorphoJ were used to visualize results.\n\n                                Results:\n                                The PCA revealed 93 loadings with the first four accounting for 65.126% of the overall\n                                variation in the shape. The first PC indicated inferior displacement of the cerebellar\n                                tonsils, posterior displacement of the posterior cerebellar lobe and 4th ventricle with\n                                concomitant ventral migration of the midbrain, and dorsal migration of the medulla. Mean\n                                scores along PC1 were significantly different between affected and control groups (t(93)\n                                = 6.8, p <0.001). In an affected-only analysis, mean shape conformation did not\n                                effectively discriminate between individuals with a history of syringomyelia and\n                                those without. There was a significant difference along PC2 for individuals\n                                receiving a diagnosis under age 30 versus those over age 30 (t(65)=2.4,\n                                p=0.017).\n\n                                Conclusions:\n                                Geometric analysis effectively discriminates between Chiari-affected\n                                individuals and matched controls. Aside from predictably highlighting tonsillar\n                                ectopia, results demonstrated a number of additional anatomical conformations in\n                                individuals with Chiari I malformation. Future directions should include machine\n                                learning to evaluate subtle shape differences between groups with the goal of\n                                integrating results into clinical decision-making."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "G6e51qTNjCd7AvDgwzy-r",
            "_type": "block",
            "children": [
              {
                "_key": "C6_jfrHGRZOwOcpljamkh",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "h_ULkZlMAQR4nu5GqKYJs",
            "_type": "block",
            "children": [
              {
                "_key": "WQ1bTmPZtk8l21ns69WEj",
                "_type": "span",
                "marks": [],
                "text": "1. Gaillard F, Yap J, Smith D, et al.: Chiari i malformation.\n                                Radiopaedia.org:2008 \n                                2. Hiremath SB, Fitsiori A, Boto J, Torres C, Zakhari N, Dietemann J-L, et al: The\n                                perplexity surrounding Chiari malformations – are we any wiser now? American\n                                    Journal of Neuroradiology 41:1975–1981, 2020"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Introduction:\n                                Chiari malformation is typically defined as inferior descent of the cerebellar tonsils\n                                through the foramen magnum. Recent investigations attempting to characterize Chiari I\n                                malformation have...",
        "publishedAt": "2025-06-04T16:58:22.287Z",
        "references": "1. Gaillard F, Yap J, Smith D, et al.: Chiari i malformation.\n                                Radiopaedia.org:2008 \n                                2. Hiremath SB, Fitsiori A, Boto J, Torres C, Zakhari N, Dietemann J-L, et al: The\n                                perplexity surrounding Chiari malformations – are we any wiser now? American\n                                    Journal of Neuroradiology 41:1975–1981, 2020",
        "researchers": [
          ": Perera",
          "I.",
          "Moriarty",
          "S.",
          "Simmons",
          "Z.",
          "Mahoney",
          "M.",
          "Malek",
          "Z.",
          "Botkin",
          "C.",
          "Millard J.A."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-_3irlGZ1APnuumi1Ov6FX",
      "data": {
        "_createdAt": "2025-06-04T16:58:23Z",
        "_id": "research-_3irlGZ1APnuumi1Ov6FX",
        "_rev": "0R95WGIfgjXsgEpFfwHhSc",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:23Z",
        "category": "original-research",
        "content": [
          {
            "_key": "VXuT0U8ybRfUTQZoQHaWw",
            "_type": "block",
            "children": [
              {
                "_key": "C5DHnun1llkZ2-x1PPMtt",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "5rSRyhpkz1Ipsh0csJq07",
            "_type": "block",
            "children": [
              {
                "_key": "MrZbpztzqXSDPHMIxlA1a",
                "_type": "span",
                "marks": [],
                "text": "Glioblastoma multiforme (GBM), WHO Grade IV astrocytoma, accounts for 50.1% of all\n                                malignant brain tumors, the most common primary brain tumor. The disease courts a poor\n                                prognosis, with a median survival of 14 months with standard therapy. Treatment of both\n                                primary and secondary GBM has been challenging, requiring a multi-faceted therapeutic\n                                plan including various implementations of gross total resection, chemotherapy,\n                                radiotherapy, and select targeted therapies. This study completes a comprehensive\n                                systematic review of all current standard treatments and treatment protocols elucidating\n                                the clinical significance of each treatment modality to provide a clinically significant\n                                protocol recommendation based on median survival time and progression-free survival.\n                                Initial treatment approaches are grounded in surgical total resection, the goal of which\n                                is to remove maximal tumor mass while ensuring maintenance of neurological status.\n                                First-line chemotherapy, Temozolomide (TMZ), is dosed concurrently with radiotherapy\n                                that is typically delivered stereotactically. This combination therapy, termed the Stupp\n                                Regimen, typically adds 2 months to the 14-month median survival. Current secondary and\n                                tertiary treatment protocols similarly alter this primary treatment approach. TMZ with\n                                Bevacizumab, for example, a second-line treatment, does not improve median survival,\n                                instead, it synergistically increases patient-reported quality of life and symptom\n                                management, while Bevacizumab alone, a third-line treatment, increased median survival\n                                by 6.6 months and progression-free survival by 2.9 months.\n                                In completion of this ongoing study, a comprehensive list of standard first, second, and\n                                third-line treatment regimens will be compiled. These regimens will then be analyzed for\n                                clinically significant benefits to the patient, most typically measured as added median\n                                survival time and progression-free survival. The novelty and variability in these\n                                standard treatment approaches make it difficult for providers to remain up to date, this\n                                study will become a comprehensive reference to standard treatment while making clear\n                                recommendations based on clinically significant findings."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "aUy6psdCKSS3qzkVdGktw",
            "_type": "block",
            "children": [
              {
                "_key": "cagOZ9iAZ5P7_inbWqWLp",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "V4QaqqriHbGZy-lnPTXQT",
            "_type": "block",
            "children": [
              {
                "_key": "-oYMJoNEe7c74wGBM0y9l",
                "_type": "span",
                "marks": [],
                "text": "1. Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., &\n                                Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: Primary Brain and other\n                                central nervous system tumors diagnosed in the United States in 2015–2019.\n                                Neuro-Oncology, 24(Supplement_5), v1–v95. https://doi.org/10.1093/neuonc/noac202\n                                2. Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017).\n                                Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical\n                                Presentation and Treatment. Asian Pacific Journal of Cancer Prevention : APJCP, 18(1),\n                                3–9. https://doi.org/10.22034/APJCP.2017.18.1.3\n                                3. Kanderi, T., & Gupta, V. (2022). Glioblastoma Multiforme. PubMed; StatPearls\n                                Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558954/\n                                4. Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., &\n                                Baranowska-Bosiacka, I. (2022). Epidemiology of glioblastoma multiforme–literature\n                                review. Cancers, 14(10), 2412. https://doi.org/10.3390/cancers14102412\n                                5. Alexander, B. M., & Cloughesy, T. F. (2017). Adult Glioblastoma. Journal of Clinical\n                                Oncology, 35(21), 2402–2409. https://doi.org/10.1200/JCO.2017.73.0119\n                                6. Mohammed, S., M, D., & T, A. (2022). Survival and quality of life analysis in\n                                glioblastoma multiforme with adjuvant chemoradiotherapy: A retrospective study. Reports\n                                of Practical Oncology and Radiotherapy, 27(6), 1026–1036.\n                                https://doi.org/10.5603/rpor.a2022.0113\n                                7. Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D.,\n                                Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic\n                                review of glioblastoma. Cancer Epidemiology, Biomarkers & Prevention, 23(10),\n                                1985–1996. https://doi.org/10.1158/1055-9965.epi-14-0275\n                                8. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.\n                                B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.\n                                C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer,\n                                E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide\n                                for glioblastoma. New England Journal of Medicine, 352(10), 987–996.\n                                https://doi.org/10.1056/nejmoa043330\n                                9. Rodríguez-Camacho, A., Flores-Vázquez, J. G., Moscardini-Martelli, J., Torres-Ríos,\n                                J. A., Olmos-Guzmán, A., Ortiz-Arce, C. S., Cid-Sánchez, D. R., Pérez, S. R.,\n                                Macías-González, M. D., Hernández-Sánchez, L. C., Heredia-Gutiérrez, J. C.,\n                                Contreras-Palafox, G. A., Suárez-Campos, J. de, Celis-López, M. Á., Gutiérrez-Aceves, G.\n                                A., & Moreno-Jiménez, S. (2022). Glioblastoma treatment: State-of-the-art and future\n                                perspectives. International Journal of Molecular Sciences, 23(13), 7207.\n                                https://doi.org/10.3390/ijms23137207\n                                10. Lakomy, R., Kazda, T., Selingerova, I., Poprach, A., Pospisil, P., Belanova, R.,\n                                Fadrus, P., Vybihal, V., Smrcka, M., Jancalek, R., Hynkova, L., Muckova, K., Hendrych,\n                                M., Sana, J., Slaby, O., & Slampa, P. (2020). Real-world evidence in glioblastoma:\n                                Stupp’s regimen after a decade. Frontiers in Oncology, 10.\n                                https://doi.org/10.3389/fonc.2020.00840\n                                11. Singh, N., Miner, A., Hennis, L., & Mittal, S. (2021). Mechanisms of temozolomide\n                                resistance in glioblastoma - A comprehensive review. Cancer Drug Resistance.\n                                https://doi.org/10.20517/cdr.2020.79\n                                12. Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018). Potential\n                                strategies overcoming the temozolomide resistance for glioblastoma. Neurologia\n                                Medico-Chirurgica, 58(10), 405–421. https://doi.org/10.2176/nmc.ra.2018-0141\n                                13. Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021). Elucidating the\n                                mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the\n                                resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(2), 188616.\n                                https://doi.org/10.1016/j.bbcan.2021.188616\n                                14. Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C.,\n                                Yao, K., Li, W., Yan, W., Li, J., You, Y., Chen, C. C., & Jiang, T. (2015). IDH mutation\n                                and MGMT promoter methylation in glioblastoma: Results of a prospective registry.\n                                Oncotarget, 6(38), 40896–40906. https://doi.org/10.18632/oncotarget.5683\n                                15. Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B.,\n                                Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu,\n                                J.-J., Stragliotto, G., Tran, D. D., Brem, S., Hottinger, A. F., Kirson, E. D.,\n                                Lavy-Shahaf, G., … Ram, Z. (2017). Effect of tumor-treating fields plus maintenance\n                                temozolomide vs maintenance temozolomide alone on survival in patients with\n                                glioblastoma. JAMA, 318(23), 2306. https://doi.org/10.1001/jama.2017.18718\n                                16. Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018).\n                                Tumor-treating fields: A fourth modality in cancer treatment. Clinical Cancer Research,\n                                24(2), 266–275. https://doi.org/10.1158/1078-0432.ccr-17-1117\n                                17. Wong, E. T., & Lok, E. (2023). Body fluids modulate propagation of tumor treating\n                                fields. Advances in Radiation Oncology, 101316.\n                                https://doi.org/10.1016/j.adro.2023.101316\n                                18. Fabian, D., Guillermo Prieto Eibl, M., Alnahhas, I., Sebastian, N., Giglio, P.,\n                                Puduvalli, V., Gonzalez, J., & Palmer, J. (2019). Treatment of glioblastoma (GB) with\n                                the addition of tumor-treating fields (TTF): A Review. Cancers, 11(2), 174.\n                                https://doi.org/10.3390/cancers11020174\n                                19. Ballo, M. T., Conlon, P., Lavy-Shahaf, G., Kinzel, A., Vymazal, J., & Rulseh, A. M.\n                                (2023a). Association of Tumor Treating Fields (TTFields) therapy with survival in newly\n                                diagnosed glioblastoma: A systematic review and meta-analysis. Journal of\n                                Neuro-Oncology, 164(1), 1–9. https://doi.org/10.1007/s11060-023-04348-w\n                                20. Ballo, M. T., Conlon, P., Lavy-Shahaf, G., Kinzel, A., Vymazal, J., & Rulseh, A. M.\n                                (2023b). LMAP-12 tumor treating fields (TTFIELDS) real-world experience in newly\n                                diagnosed glioblastoma: A systematic literature review and meta-analysis of overall\n                                survival. Neuro-Oncology Advances, 5(Supplement_3), iii11–iii12.\n                                https://doi.org/10.1093/noajnl/vdad070.043\n                                21. Ashby, L. S., Smith, K. A., & Stea, B. (2016). Gliadel wafer implantation combined\n                                with standard radiotherapy and concurrent followed by adjuvant temozolomide for\n                                treatment of newly diagnosed high-grade glioma: A systematic literature review. World\n                                Journal of Surgical Oncology, 14(1). https://doi.org/10.1186/s12957-016-0975-5\n                                22. Roux, A., Aboubakr, O., Elia, A., Moiraghi, A., Benevello, C., Fathallah, H.,\n                                Parraga, E., Oppenheim, C., Chretien, F., Dezamis, E., Zanello, M., & Pallud, J. (2023).\n                                Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in\n                                “extreme” neurosurgical conditions. Neurosurgical Review, 46(1).\n                                https://doi.org/10.1007/s10143-023-02052-x\n                                23. Franceschi, E., Lamberti, G., Alexandro Paccapelo, Monica Di Battista, Giovenzio\n                                Genestreti, Santino Minichillo, Mura, A., Bartolini, S., Agati, R., & Brandes, A. A.\n                                (2018). Third-line therapy in recurrent glioblastoma: is it another chance for\n                                bevacizumab? Journal of Neuro-Oncology, 139(2), 383–388.\n                                https://doi.org/10.1007/s11060-018-2873-x"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Glioblastoma multiforme (GBM), WHO Grade IV astrocytoma, accounts for 50.1% of all\n                                malignant brain tumors, the most common primary brain tumor. The disease courts a poor\n                                prognosis, with a median survival of 14 months with standard thera...",
        "publishedAt": "2025-06-04T16:58:23.322Z",
        "references": "1. Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., &\n                                Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: Primary Brain and other\n                                central nervous system tumors diagnosed in the United States in 2015–2019.\n                                Neuro-Oncology, 24(Supplement_5), v1–v95. https://doi.org/10.1093/neuonc/noac202\n                                2. Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017).\n                                Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical\n                                Presentation and Treatment. Asian Pacific Journal of Cancer Prevention : APJCP, 18(1),\n                                3–9. https://doi.org/10.22034/APJCP.2017.18.1.3\n                                3. Kanderi, T., & Gupta, V. (2022). Glioblastoma Multiforme. PubMed; StatPearls\n                                Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558954/\n                                4. Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., &\n                                Baranowska-Bosiacka, I. (2022). Epidemiology of glioblastoma multiforme–literature\n                                review. Cancers, 14(10), 2412. https://doi.org/10.3390/cancers14102412\n                                5. Alexander, B. M., & Cloughesy, T. F. (2017). Adult Glioblastoma. Journal of Clinical\n                                Oncology, 35(21), 2402–2409. https://doi.org/10.1200/JCO.2017.73.0119\n                                6. Mohammed, S., M, D., & T, A. (2022). Survival and quality of life analysis in\n                                glioblastoma multiforme with adjuvant chemoradiotherapy: A retrospective study. Reports\n                                of Practical Oncology and Radiotherapy, 27(6), 1026–1036.\n                                https://doi.org/10.5603/rpor.a2022.0113\n                                7. Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D.,\n                                Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic\n                                review of glioblastoma. Cancer Epidemiology, Biomarkers & Prevention, 23(10),\n                                1985–1996. https://doi.org/10.1158/1055-9965.epi-14-0275\n                                8. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.\n                                B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.\n                                C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer,\n                                E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide\n                                for glioblastoma. New England Journal of Medicine, 352(10), 987–996.\n                                https://doi.org/10.1056/nejmoa043330\n                                9. Rodríguez-Camacho, A., Flores-Vázquez, J. G., Moscardini-Martelli, J., Torres-Ríos,\n                                J. A., Olmos-Guzmán, A., Ortiz-Arce, C. S., Cid-Sánchez, D. R., Pérez, S. R.,\n                                Macías-González, M. D., Hernández-Sánchez, L. C., Heredia-Gutiérrez, J. C.,\n                                Contreras-Palafox, G. A., Suárez-Campos, J. de, Celis-López, M. Á., Gutiérrez-Aceves, G.\n                                A., & Moreno-Jiménez, S. (2022). Glioblastoma treatment: State-of-the-art and future\n                                perspectives. International Journal of Molecular Sciences, 23(13), 7207.\n                                https://doi.org/10.3390/ijms23137207\n                                10. Lakomy, R., Kazda, T., Selingerova, I., Poprach, A., Pospisil, P., Belanova, R.,\n                                Fadrus, P., Vybihal, V., Smrcka, M., Jancalek, R., Hynkova, L., Muckova, K., Hendrych,\n                                M., Sana, J., Slaby, O., & Slampa, P. (2020). Real-world evidence in glioblastoma:\n                                Stupp’s regimen after a decade. Frontiers in Oncology, 10.\n                                https://doi.org/10.3389/fonc.2020.00840\n                                11. Singh, N., Miner, A., Hennis, L., & Mittal, S. (2021). Mechanisms of temozolomide\n                                resistance in glioblastoma - A comprehensive review. Cancer Drug Resistance.\n                                https://doi.org/10.20517/cdr.2020.79\n                                12. Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018). Potential\n                                strategies overcoming the temozolomide resistance for glioblastoma. Neurologia\n                                Medico-Chirurgica, 58(10), 405–421. https://doi.org/10.2176/nmc.ra.2018-0141\n                                13. Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021). Elucidating the\n                                mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the\n                                resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(2), 188616.\n                                https://doi.org/10.1016/j.bbcan.2021.188616\n                                14. Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C.,\n                                Yao, K., Li, W., Yan, W., Li, J., You, Y., Chen, C. C., & Jiang, T. (2015). IDH mutation\n                                and MGMT promoter methylation in glioblastoma: Results of a prospective registry.\n                                Oncotarget, 6(38), 40896–40906. https://doi.org/10.18632/oncotarget.5683\n                                15. Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B.,\n                                Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu,\n                                J.-J., Stragliotto, G., Tran, D. D., Brem, S., Hottinger, A. F., Kirson, E. D.,\n                                Lavy-Shahaf, G., … Ram, Z. (2017). Effect of tumor-treating fields plus maintenance\n                                temozolomide vs maintenance temozolomide alone on survival in patients with\n                                glioblastoma. JAMA, 318(23), 2306. https://doi.org/10.1001/jama.2017.18718\n                                16. Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018).\n                                Tumor-treating fields: A fourth modality in cancer treatment. Clinical Cancer Research,\n                                24(2), 266–275. https://doi.org/10.1158/1078-0432.ccr-17-1117\n                                17. Wong, E. T., & Lok, E. (2023). Body fluids modulate propagation of tumor treating\n                                fields. Advances in Radiation Oncology, 101316.\n                                https://doi.org/10.1016/j.adro.2023.101316\n                                18. Fabian, D., Guillermo Prieto Eibl, M., Alnahhas, I., Sebastian, N., Giglio, P.,\n                                Puduvalli, V., Gonzalez, J., & Palmer, J. (2019). Treatment of glioblastoma (GB) with\n                                the addition of tumor-treating fields (TTF): A Review. Cancers, 11(2), 174.\n                                https://doi.org/10.3390/cancers11020174\n                                19. Ballo, M. T., Conlon, P., Lavy-Shahaf, G., Kinzel, A., Vymazal, J., & Rulseh, A. M.\n                                (2023a). Association of Tumor Treating Fields (TTFields) therapy with survival in newly\n                                diagnosed glioblastoma: A systematic review and meta-analysis. Journal of\n                                Neuro-Oncology, 164(1), 1–9. https://doi.org/10.1007/s11060-023-04348-w\n                                20. Ballo, M. T., Conlon, P., Lavy-Shahaf, G., Kinzel, A., Vymazal, J., & Rulseh, A. M.\n                                (2023b). LMAP-12 tumor treating fields (TTFIELDS) real-world experience in newly\n                                diagnosed glioblastoma: A systematic literature review and meta-analysis of overall\n                                survival. Neuro-Oncology Advances, 5(Supplement_3), iii11–iii12.\n                                https://doi.org/10.1093/noajnl/vdad070.043\n                                21. Ashby, L. S., Smith, K. A., & Stea, B. (2016). Gliadel wafer implantation combined\n                                with standard radiotherapy and concurrent followed by adjuvant temozolomide for\n                                treatment of newly diagnosed high-grade glioma: A systematic literature review. World\n                                Journal of Surgical Oncology, 14(1). https://doi.org/10.1186/s12957-016-0975-5\n                                22. Roux, A., Aboubakr, O., Elia, A., Moiraghi, A., Benevello, C., Fathallah, H.,\n                                Parraga, E., Oppenheim, C., Chretien, F., Dezamis, E., Zanello, M., & Pallud, J. (2023).\n                                Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in\n                                “extreme” neurosurgical conditions. Neurosurgical Review, 46(1).\n                                https://doi.org/10.1007/s10143-023-02052-x\n                                23. Franceschi, E., Lamberti, G., Alexandro Paccapelo, Monica Di Battista, Giovenzio\n                                Genestreti, Santino Minichillo, Mura, A., Bartolini, S., Agati, R., & Brandes, A. A.\n                                (2018). Third-line therapy in recurrent glioblastoma: is it another chance for\n                                bevacizumab? Journal of Neuro-Oncology, 139(2), 383–388.\n                                https://doi.org/10.1007/s11060-018-2873-x",
        "researchers": [
          ": Greenberg",
          "S.",
          "Brower",
          "M.",
          "Rashid",
          "M.",
          "Gademsey",
          "A.",
          "Shahidi",
          "R.",
          "Santiago",
          "M.",
          "Kasper",
          "B.",
          "Kasper.",
          "H.",
          "Perera",
          "I.",
          "Marvin",
          "E."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-oljUbzaZ4mtUv-Yowo9cz",
      "data": {
        "_createdAt": "2025-06-04T16:58:25Z",
        "_id": "research-oljUbzaZ4mtUv-Yowo9cz",
        "_rev": "0R95WGIfgjXsgEpFfwHhYS",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:25Z",
        "category": "original-research",
        "content": [
          {
            "_key": "HCEMm1HegEUmgjbzNfuWs",
            "_type": "block",
            "children": [
              {
                "_key": "sSEulhDg26-vkRGLauOt1",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "AnBQqZ7kN8y88W7-cFnyh",
            "_type": "block",
            "children": [
              {
                "_key": "yS6HLzd6bUFKkXGkmh3rh",
                "_type": "span",
                "marks": [],
                "text": "Glioblastoma multiforme (GBM), WHO Grade IV astrocytoma, accounts for 50.1% of all\n                                malignant brain tumors, the most common primary brain tumor. Typically, both primary and\n                                secondary GBM treatment regimens modify the traditional Stupp Regimen including gross\n                                total resection, chemotherapy, and radiotherapy; however, regardless of the developed\n                                therapeutic plan the disease courts a poor median survival of 14 months. This\n                                comprehensive systematic review of novel therapeutic approaches to GBM treatment aims to\n                                provide an extensive catalog of treatment regimens, clinically significant benefits such\n                                as median survival time and progression-free survival, and to provide a recommendation\n                                of the best novel approaches for further study.\n                                Novel treatment methods including tumor-treating fields (TTFields), carmustine wafers,\n                                viral therapy, and lab-synthesized molecules, such as Hyaluronic acid (7\n                                kDa)-b-polylactic acid (HA7-PLA) polymersome purport positive outcomes between 17.5 to\n                                36 months of median survival. TTFields in addition to Temozolomide (TMZ) when compared\n                                to TMZ alone resulted in 2.7 additional months of progression-free survival and 4.9 to\n                                5.2 months of added median survival time. Placement of greater than 12 carmustine wafers\n                                at initial resection improved progression-free survival by 21 months and median survival\n                                by 22.5 months. Additionally, wafer placement after recurrence surgery increased median\n                                survival time by 3.5 months. Viral therapy, recombinant non-pathogenic polio-rhinovirus\n                                chimera (PVSRIPO), extended median survival by 24 to 36 months. Synthesized molecules,\n                                such as HA7-PLA polymersome, are some of the most novel approaches to GBM treatment,\n                                thus they are currently discussed without human application data.\n                                Completion of this comprehensive review will produce an up-to-date list of novel and\n                                experimental treatment approaches with reported clinically significant data points -\n                                median survival time and progression-free survival. In turn, this study will elucidate\n                                the most clinically significant novel approaches to GBM treatment based on the most\n                                current published treatment approaches, this may then be used as a guide for future\n                                study design and reference."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "GIksRjicFmxErdRF6g8um",
            "_type": "block",
            "children": [
              {
                "_key": "Vhbw7Rgx454E6H1S7A2k1",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "8fkQKK8o53LApdf93q3cO",
            "_type": "block",
            "children": [
              {
                "_key": "xdbDi8c-PcsjbavbT1HU8",
                "_type": "span",
                "marks": [],
                "text": "1. Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., &\n                                Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: Primary Brain and other\n                                central nervous system tumors diagnosed in the United States in 2015–2019.\n                                Neuro-Oncology, 24(Supplement_5), v1–v95. https://doi.org/10.1093/neuonc/noac202\n                                \n                                2. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.\n                                B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.\n                                C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer,\n                                E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide\n                                for glioblastoma. New England Journal of Medicine, 352(10), 987–996.\n                                https://doi.org/10.1056/nejmoa043330\n                                3. Rodríguez-Camacho, A., Flores-Vázquez, J. G., Moscardini-Martelli, J., Torres-Ríos,\n                                J.\n                                A., Olmos-Guzmán, A., Ortiz-Arce, C. S., Cid-Sánchez, D. R., Pérez, S. R.,\n                                Macías-González, M. D., Hernández-Sánchez, L. C., Heredia-Gutiérrez, J. C.,\n                                Contreras-Palafox, G. A., Suárez-Campos, J. de, Celis-López, M. Á., Gutiérrez-Aceves, G.\n                                A., & Moreno-Jiménez, S. (2022). Glioblastoma treatment: State-of-the-art and future\n                                perspectives. International Journal of Molecular Sciences, 23(13), 7207.\n                                https://doi.org/10.3390/ijms23137207\n                                4. Xiao, Z.-Z., Wang, Z.-F., Lan, T., Huang, W.-H., Zhao, Y.-H., Ma, C., & Li, Z.-Q.\n                                (2020). Carmustine as a supplementary therapeutic option for glioblastoma: A systematic\n                                review and meta-analysis. Frontiers in Neurology, 11.\n                                https://doi.org/10.3389/fneur.2020.01036 \n                                5. Şenkesen, Ö., Tezcanlı, E., Abacıoğlu, M. U., Özen, Z., Çöne, D., Küçücük, H.,\n                                Göksel,\n                                E. O., Arifoğlu, A., & Şengöz, M. (2022). Limited field adaptive radiotherapy for\n                                glioblastoma: Changes in target volume and organ at risk doses. Radiation Oncology\n                                Journal, 40(1), 9–19. https://doi.org/10.3857/roj.2021.00542 \n                                6. Guevara, B., Cullison, K., Maziero, D., Azzam, G. A., De La Fuente, M. I., Brown, K.,\n                                Valderrama, A., Meshman, J., Breto, A., Ford, J. C., & Mellon, E. A. (2023). Simulated\n                                adaptive radiotherapy for shrinking glioblastoma resection cavities on a hybrid\n                                MRI–linear accelerator. Cancers, 15(5), 1555.\n                                https://doi.org/10.3390/cancers15051555\n                                7. Matsuyama, T., Fukugawa, Y., Kuroda, J., Toya, R., Watakabe, T., Matsumoto, T., &\n                                Oya,\n                                N. (2022). A prospective comparison of adaptive and fixed boost plans in radiotherapy\n                                for glioblastoma. Radiation Oncology, 17(1).\n                                https://doi.org/10.1186/s13014-022-02007-4\n                                8. VÉGVÁRY, Z., DARÁZS, B., PACZONA, V., DOBI, Á., REISZ, Z., VARGA, Z., FODOR, E.,\n                                CSERHÁTI, A., OLÁH, J., KIS, D., BARZÓ, P., & HIDEGHÉTY, K. (2020). Adaptive\n                                radiotherapy for glioblastoma multiforme – the impact on disease outcome. Anticancer\n                                Research, 40(8), 4237–4244. https://doi.org/10.21873/anticanres.14425\n                                9. Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy,\n                                T.,\n                                Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., Lombardi, G., Mulholland, P.,\n                                Tabatabai, G., Lassen, U., Sepulveda, J. M., Khasraw, M., Vauleon, E., Muragaki, Y., Di\n                                Giacomo, A. M., … Weller, M. (2023). Radiotherapy combined with nivolumab or\n                                temozolomide for newly diagnosed glioblastoma with unmethylated mgmtpromoter: An\n                                international randomized phase III trial. Neuro-Oncology, 25(1), 123–134.\n                                https://doi.org/10.1093/neuonc/noac099\n                                10. Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S.,\n                                Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., Iwamoto, F. M., Dropcho, E. J.,\n                                Moshel, Y. A., Walter, K. A., Pillainayagam, C. P., Aiken, R., Chaudhary, R., Goldlust,\n                                S. A., Bota, D. A., … Bosch, M. L. (2018). First results on survival from a large phase\n                                3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed\n                                glioblastoma. Journal of Translational Medicine, 16(1).\n                                https://doi.org/10.1186/s12967-018-1507-6\n                                11. Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P.,\n                                Friedman,\n                                A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., Peters, K. B., Randazzo,\n                                D., Sampson, J. H., Vlahovic, G., Harrison, W. T., McLendon, R. E., Ashley, D., &\n                                Bigner, D. D. (2018). Recurrent glioblastoma treated with recombinant poliovirus. New\n                                England Journal of Medicine, 379(2), 150–161. https://doi.org/10.1056/nejmoa1716435\n                                \n                                12. Dighe, O. R., Korde, P., Bisen, Y. T., Iratwar, S., Kesharwani, A., Vardhan, S., &\n                                Singh, A. (2023). Emerging recombinant oncolytic poliovirus therapies against malignant\n                                glioma: A Review. Cureus. https://doi.org/10.7759/cureus.34028\n                                13. Harter, D., Wilson, T., & Karajannis, M. (2014). Glioblastoma multiforme: State of\n                                the\n                                art and Future Therapeutics. Surgical Neurology International, 5(1), 64.\n                                https://doi.org/10.4103/2152-7806.132138\n                                14. Hawasli, A. H., Bagade, S., Shimony, J. S., Miller-Thomas, M., & Leuthardt, E. C.\n                                (2013). Magnetic resonance imaging-guided focused laser interstitial thermal therapy for\n                                intracranial lesions. Neurosurgery, 73(6), 1007–1017.\n                                https://doi.org/10.1227/neu.0000000000000144\n                                15. Sloan, A. E., Ahluwalia, M. S., Valerio-Pascua, J., Manjila, S., Torchia, M. G.,\n                                Jones,\n                                S. E., Sunshine, J. L., Phillips, M., Griswold, M. A., Clampitt, M., Brewer, C., Jochum,\n                                J., McGraw, M. V., Diorio, D., Ditz, G., & Barnett, G. H. (2013). Results of the\n                                NeuroBlate system first-in-humans phase I clinical trial for recurrent glioblastoma.\n                                Journal of Neurosurgery, 118(6), 1202–1219.\n                                https://doi.org/10.3171/2013.1.jns1291\n                                16. Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018).\n                                Current\n                                challenges and opportunities in treating glioblastomas. Pharmacological Reviews, 70(3),\n                                412–445. https://doi.org/10.1124/pr.117.014944\n                                17. Campelo, S. N., Lorenzo, M. F., Partridge, B., Alinezhadbalalami, N., Kani, Y.,\n                                Garcia,\n                                J., Saunier, S., Thomas, S. C., Hinckley, J., Verbridge, S. S., Davalos, R. V., &\n                                Rossmeisl, J. H. (2023). High-frequency irreversible electroporation improves survival\n                                and immune cell infiltration in rodents with malignant gliomas. Frontiers in Oncology,\n                                13. https://doi.org/10.3389/fonc.2023.1171278\n                                18. Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier,\n                                N.,\n                                Law-Ye, B., Leclercq, D., Bissery, A., De Rycke, Y., Trosch, C., Capelle, L., Sanson,\n                                M., Hoang-Xuan, K., Dehais, C., Houillier, C., Laigle-Donadey, F., Mathon, B., …\n                                Carpentier, A. (2019). Safety and Feasibility of Repeated and Transient Blood–Brain\n                                Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.\n                                Clinical Cancer Research, 25(13), 3793–3801.\n                                https://doi.org/10.1158/1078-0432.CCR-18-3643\n                                19. Ringel-Scaia, V. M., Beitel-White, N., Lorenzo, M. F., Brock, R. M., Huie, K. E.,\n                                Coutermarsh-Ott, S., Eden, K., McDaniel, D. K., Verbridge, S. S., Rossmeisl, J. H.,\n                                Oestreich, K. J., Davalos, R. V., & Allen, I. C. (2019). High-frequency irreversible\n                                electroporation is an effective tumor ablation strategy that induces immunologic cell\n                                death and promotes systemic anti-tumor immunity. EBioMedicine, 44, 112–125.\n                                https://doi.org/10.1016/j.ebiom.2019.05.036\n                                20. D’Amico, R. S., Aghi, M. K., Vogelbaum, M. A., & Bruce, J. N. (2021).\n                                Convection-enhanced drug delivery for glioblastoma: A Review. Journal of Neuro-Oncology,\n                                151(3), 415–427. https://doi.org/10.1007/s11060-020-03408-9 \n                                21. Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa,\n                                H.,\n                                Budach, V., & Jordan, A. (2010). Efficacy and safety of intratumoral thermotherapy using\n                                magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients\n                                with recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 103(2), 317–324.\n                                https://doi.org/10.1007/s11060-010-0389-0"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Glioblastoma multiforme (GBM), WHO Grade IV astrocytoma, accounts for 50.1% of all\n                                malignant brain tumors, the most common primary brain tumor. Typically, both primary and\n                                secondary GBM treatment regimens modify the traditional Stupp Re...",
        "publishedAt": "2025-06-04T16:58:24.937Z",
        "references": "1. Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., &\n                                Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: Primary Brain and other\n                                central nervous system tumors diagnosed in the United States in 2015–2019.\n                                Neuro-Oncology, 24(Supplement_5), v1–v95. https://doi.org/10.1093/neuonc/noac202\n                                \n                                2. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J.\n                                B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.\n                                C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer,\n                                E., & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide\n                                for glioblastoma. New England Journal of Medicine, 352(10), 987–996.\n                                https://doi.org/10.1056/nejmoa043330\n                                3. Rodríguez-Camacho, A., Flores-Vázquez, J. G., Moscardini-Martelli, J., Torres-Ríos,\n                                J.\n                                A., Olmos-Guzmán, A., Ortiz-Arce, C. S., Cid-Sánchez, D. R., Pérez, S. R.,\n                                Macías-González, M. D., Hernández-Sánchez, L. C., Heredia-Gutiérrez, J. C.,\n                                Contreras-Palafox, G. A., Suárez-Campos, J. de, Celis-López, M. Á., Gutiérrez-Aceves, G.\n                                A., & Moreno-Jiménez, S. (2022). Glioblastoma treatment: State-of-the-art and future\n                                perspectives. International Journal of Molecular Sciences, 23(13), 7207.\n                                https://doi.org/10.3390/ijms23137207\n                                4. Xiao, Z.-Z., Wang, Z.-F., Lan, T., Huang, W.-H., Zhao, Y.-H., Ma, C., & Li, Z.-Q.\n                                (2020). Carmustine as a supplementary therapeutic option for glioblastoma: A systematic\n                                review and meta-analysis. Frontiers in Neurology, 11.\n                                https://doi.org/10.3389/fneur.2020.01036 \n                                5. Şenkesen, Ö., Tezcanlı, E., Abacıoğlu, M. U., Özen, Z., Çöne, D., Küçücük, H.,\n                                Göksel,\n                                E. O., Arifoğlu, A., & Şengöz, M. (2022). Limited field adaptive radiotherapy for\n                                glioblastoma: Changes in target volume and organ at risk doses. Radiation Oncology\n                                Journal, 40(1), 9–19. https://doi.org/10.3857/roj.2021.00542 \n                                6. Guevara, B., Cullison, K., Maziero, D., Azzam, G. A., De La Fuente, M. I., Brown, K.,\n                                Valderrama, A., Meshman, J., Breto, A., Ford, J. C., & Mellon, E. A. (2023). Simulated\n                                adaptive radiotherapy for shrinking glioblastoma resection cavities on a hybrid\n                                MRI–linear accelerator. Cancers, 15(5), 1555.\n                                https://doi.org/10.3390/cancers15051555\n                                7. Matsuyama, T., Fukugawa, Y., Kuroda, J., Toya, R., Watakabe, T., Matsumoto, T., &\n                                Oya,\n                                N. (2022). A prospective comparison of adaptive and fixed boost plans in radiotherapy\n                                for glioblastoma. Radiation Oncology, 17(1).\n                                https://doi.org/10.1186/s13014-022-02007-4\n                                8. VÉGVÁRY, Z., DARÁZS, B., PACZONA, V., DOBI, Á., REISZ, Z., VARGA, Z., FODOR, E.,\n                                CSERHÁTI, A., OLÁH, J., KIS, D., BARZÓ, P., & HIDEGHÉTY, K. (2020). Adaptive\n                                radiotherapy for glioblastoma multiforme – the impact on disease outcome. Anticancer\n                                Research, 40(8), 4237–4244. https://doi.org/10.21873/anticanres.14425\n                                9. Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy,\n                                T.,\n                                Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., Lombardi, G., Mulholland, P.,\n                                Tabatabai, G., Lassen, U., Sepulveda, J. M., Khasraw, M., Vauleon, E., Muragaki, Y., Di\n                                Giacomo, A. M., … Weller, M. (2023). Radiotherapy combined with nivolumab or\n                                temozolomide for newly diagnosed glioblastoma with unmethylated mgmtpromoter: An\n                                international randomized phase III trial. Neuro-Oncology, 25(1), 123–134.\n                                https://doi.org/10.1093/neuonc/noac099\n                                10. Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S.,\n                                Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., Iwamoto, F. M., Dropcho, E. J.,\n                                Moshel, Y. A., Walter, K. A., Pillainayagam, C. P., Aiken, R., Chaudhary, R., Goldlust,\n                                S. A., Bota, D. A., … Bosch, M. L. (2018). First results on survival from a large phase\n                                3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed\n                                glioblastoma. Journal of Translational Medicine, 16(1).\n                                https://doi.org/10.1186/s12967-018-1507-6\n                                11. Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P.,\n                                Friedman,\n                                A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., Peters, K. B., Randazzo,\n                                D., Sampson, J. H., Vlahovic, G., Harrison, W. T., McLendon, R. E., Ashley, D., &\n                                Bigner, D. D. (2018). Recurrent glioblastoma treated with recombinant poliovirus. New\n                                England Journal of Medicine, 379(2), 150–161. https://doi.org/10.1056/nejmoa1716435\n                                \n                                12. Dighe, O. R., Korde, P., Bisen, Y. T., Iratwar, S., Kesharwani, A., Vardhan, S., &\n                                Singh, A. (2023). Emerging recombinant oncolytic poliovirus therapies against malignant\n                                glioma: A Review. Cureus. https://doi.org/10.7759/cureus.34028\n                                13. Harter, D., Wilson, T., & Karajannis, M. (2014). Glioblastoma multiforme: State of\n                                the\n                                art and Future Therapeutics. Surgical Neurology International, 5(1), 64.\n                                https://doi.org/10.4103/2152-7806.132138\n                                14. Hawasli, A. H., Bagade, S., Shimony, J. S., Miller-Thomas, M., & Leuthardt, E. C.\n                                (2013). Magnetic resonance imaging-guided focused laser interstitial thermal therapy for\n                                intracranial lesions. Neurosurgery, 73(6), 1007–1017.\n                                https://doi.org/10.1227/neu.0000000000000144\n                                15. Sloan, A. E., Ahluwalia, M. S., Valerio-Pascua, J., Manjila, S., Torchia, M. G.,\n                                Jones,\n                                S. E., Sunshine, J. L., Phillips, M., Griswold, M. A., Clampitt, M., Brewer, C., Jochum,\n                                J., McGraw, M. V., Diorio, D., Ditz, G., & Barnett, G. H. (2013). Results of the\n                                NeuroBlate system first-in-humans phase I clinical trial for recurrent glioblastoma.\n                                Journal of Neurosurgery, 118(6), 1202–1219.\n                                https://doi.org/10.3171/2013.1.jns1291\n                                16. Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018).\n                                Current\n                                challenges and opportunities in treating glioblastomas. Pharmacological Reviews, 70(3),\n                                412–445. https://doi.org/10.1124/pr.117.014944\n                                17. Campelo, S. N., Lorenzo, M. F., Partridge, B., Alinezhadbalalami, N., Kani, Y.,\n                                Garcia,\n                                J., Saunier, S., Thomas, S. C., Hinckley, J., Verbridge, S. S., Davalos, R. V., &\n                                Rossmeisl, J. H. (2023). High-frequency irreversible electroporation improves survival\n                                and immune cell infiltration in rodents with malignant gliomas. Frontiers in Oncology,\n                                13. https://doi.org/10.3389/fonc.2023.1171278\n                                18. Idbaih, A., Canney, M., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier,\n                                N.,\n                                Law-Ye, B., Leclercq, D., Bissery, A., De Rycke, Y., Trosch, C., Capelle, L., Sanson,\n                                M., Hoang-Xuan, K., Dehais, C., Houillier, C., Laigle-Donadey, F., Mathon, B., …\n                                Carpentier, A. (2019). Safety and Feasibility of Repeated and Transient Blood–Brain\n                                Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.\n                                Clinical Cancer Research, 25(13), 3793–3801.\n                                https://doi.org/10.1158/1078-0432.CCR-18-3643\n                                19. Ringel-Scaia, V. M., Beitel-White, N., Lorenzo, M. F., Brock, R. M., Huie, K. E.,\n                                Coutermarsh-Ott, S., Eden, K., McDaniel, D. K., Verbridge, S. S., Rossmeisl, J. H.,\n                                Oestreich, K. J., Davalos, R. V., & Allen, I. C. (2019). High-frequency irreversible\n                                electroporation is an effective tumor ablation strategy that induces immunologic cell\n                                death and promotes systemic anti-tumor immunity. EBioMedicine, 44, 112–125.\n                                https://doi.org/10.1016/j.ebiom.2019.05.036\n                                20. D’Amico, R. S., Aghi, M. K., Vogelbaum, M. A., & Bruce, J. N. (2021).\n                                Convection-enhanced drug delivery for glioblastoma: A Review. Journal of Neuro-Oncology,\n                                151(3), 415–427. https://doi.org/10.1007/s11060-020-03408-9 \n                                21. Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa,\n                                H.,\n                                Budach, V., & Jordan, A. (2010). Efficacy and safety of intratumoral thermotherapy using\n                                magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients\n                                with recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 103(2), 317–324.\n                                https://doi.org/10.1007/s11060-010-0389-0",
        "researchers": [
          ": Santiago",
          "M.",
          "Gademsey",
          "A.",
          "Shahidi",
          "R.",
          "Greenberg",
          "S.",
          "Brower",
          "M.",
          "Rashid",
          "M.",
          "Kasper",
          "B.",
          "Kasper",
          "H.",
          "Perera",
          "I.",
          "Marvin",
          "E."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-atQXPKtM5nh_44FeaFbfB",
      "data": {
        "_createdAt": "2025-06-04T16:58:26Z",
        "_id": "research-atQXPKtM5nh_44FeaFbfB",
        "_rev": "jfcORSZ86cdtiqyuKTPvoh",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:26Z",
        "category": "case-report",
        "content": [
          {
            "_key": "0xBuVDw2h3GLAdNMYrFTA",
            "_type": "block",
            "children": [
              {
                "_key": "NjVCLSVq61I6MRCFdzp_4",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "Ngxv52BgLphgjhMjJfBp5",
            "_type": "block",
            "children": [
              {
                "_key": "79ZZInGHMGzPmJECJ6Y8g",
                "_type": "span",
                "marks": [],
                "text": "Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease that results\n                                in fibrotic lung tissue leading to symptoms of dyspnea, nonproductive cough, decreased\n                                mobility and fatigue. This article presents a well-documented case of a 73-year-old\n                                female presenting to a chiropractic and rehabilitation center seeking care after failing\n                                medication therapy. The patient presented hypoxic on room air with decreased mobility\n                                throughout her cervical, thoracic, and lumbar spine. Three manual therapy techniques\n                                were performed at the rehabilitation clinic aimed at improving range of motion of the\n                                impacted joints and surrounding tissue. The patient was also given manual therapy\n                                exercises to perform at home. Pre- and post-intervention assessments showed an\n                                improvement in oxygenation saturation on room air, increased mobility, and stabilization\n                                of the patients pulmonary function test (PFT) values. This case demonstrates the\n                                importance of considering manual therapy in patients that have failed standard of care\n                                or are unable to tolerate the medications used to treat IPF."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "QvgNDaI3pIcwSlIPlXB47",
            "_type": "block",
            "children": [
              {
                "_key": "kM4Ye7PhVik5s9B3KeHkX",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "xS2W8hro063goU5RTqsSN",
            "_type": "block",
            "children": [
              {
                "_key": "iJiomAKzKZq6bzTMs5LzF",
                "_type": "span",
                "marks": [],
                "text": "1. Zisman DA, Keane MP, Belperio JA, Strieter RM, Lynch JP 3rd: Pulmonary fibrosis.\n                                Methods Mol Med. 2005, 117:3-44. 10.1385/1-59259-940-0: 003\n                                2. Krishna R, Chapman K, Ullah S: Idiopathic Pulmonary Fibrosis. StatPearls [Internet]\n                                (ed): StatPearls Publishing, Treasure Island, FL; 2023.\n                                3. Zaman T, Lee JS: Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a\n                                Review. Curr Pulmonol Rep. 2018, 7:118-125. 10.1007/s13665-018-0210-7\n                                4. Wolters PJ, Blackwell TS, Eickelberg O, et al.: Time for a change: is idiopathic\n                                pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respir Med. 2018,\n                                6:154-160. 10.1016/S2213-2600(18)30007-9\n                                5. Kolb M, Collard HR: Staging of idiopathic pulmonary fibrosis: past, present and\n                                future. Eur Respir Rev. 2014, 23:220-224. 10.1183/09059180.00002114\n                                6. Pleasants R, Tighe RM: Management of Idiopathic Pulmonary Fibrosis. Ann Pharmacother.\n                                2019, 53:1238-1248. 10.1177/1060028019862497\n                                7. Pulmonary fibrosis. (2021). Accessed: 24 July 2023:\n                                https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis.\n                                8. Vainshelboim B: Exercise training in idiopathic pulmonary fibrosis: is it of\n                                benefit?. Breathe (Sheff). 2016, 12:130-8. 10.1183/20734735.006916\n                                9. Swigris JJ, Brown KK, Make BJ, Wamboldt FS: Pulmonary rehabilitation in idiopathic\n                                pulmonary fibrosis: a call for continued investigation. Respir Med. 2008, 102:1675-80.\n                                10.1016/j.rmed.2008.08.014\n                                10. Shariat C, Garvey C, Rigler J, Collard HR: Pulmonary rehabilitation improves\n                                functional capacity in patients with interstitial lung disease. Chest. 2007, 132:458.\n                                10.1378/chest.132.4_MeetingAbstracts.458\n                                11. Dowman L, Hill CJ, May A, Holland AE: Pulmonary rehabilitation for interstitial lung\n                                disease. Cochrane Database Syst Rev. 2021, 2:CD006322.\n                                10.1002/14651858.CD006322.pub4\n                                12. Naji N, Connor M, Donnelly S, et al.: Effectiveness of Pulmonary Rehabilitation in\n                                Restrictive Lung Disease. J Cardiopulm Rehabil. 2006, 26:237-43.\n                                10.1097/00008483-200607000-00007\n                                13. Cheng L, Tan B, Yin Y, et al.: Short- and long-term effects of pulmonary\n                                rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.\n                                Clini Rehabil. 2018, 32:1299-1307. 10.1177/0269215518779122\n                                14. Arnold MT, Dolezal BA, Cooper CB: Pulmonary Rehabilitation for Chronic Obstructive\n                                Pulmonary Disease: Highly Effective but Often Overlooked. Tuberc Respir Dis (Seoul).\n                                2020, 83:257-267. 10.4046/trd.2020.0064\n                                15. Liu W, Mu X, Wang X, Zhang P, Zhao L, Li Q: Effects of comprehensive pulmonary\n                                rehabilitation therapy on pulmonary functions and blood gas indexes of patients with\n                                severe pneumonia. Exp Ther Med. 2018, 16:1953-1957. 10.3892/etm.2018.6396\n                                16. Mahler B, Croitoru A: Pulmonary rehabilitation and tuberculosis: a new approach for\n                                an old disease.. Pneumologia. 2019, 68:107-113. 10.2478/pneum-2019-0024"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease that results\n                                in fibrotic lung tissue leading to symptoms of dyspnea, nonproductive cough, decreased\n                                mobility and fatigue. This article presents a well-documented...",
        "publishedAt": "2025-06-04T16:58:26.361Z",
        "references": "1. Zisman DA, Keane MP, Belperio JA, Strieter RM, Lynch JP 3rd: Pulmonary fibrosis.\n                                Methods Mol Med. 2005, 117:3-44. 10.1385/1-59259-940-0: 003\n                                2. Krishna R, Chapman K, Ullah S: Idiopathic Pulmonary Fibrosis. StatPearls [Internet]\n                                (ed): StatPearls Publishing, Treasure Island, FL; 2023.\n                                3. Zaman T, Lee JS: Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a\n                                Review. Curr Pulmonol Rep. 2018, 7:118-125. 10.1007/s13665-018-0210-7\n                                4. Wolters PJ, Blackwell TS, Eickelberg O, et al.: Time for a change: is idiopathic\n                                pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respir Med. 2018,\n                                6:154-160. 10.1016/S2213-2600(18)30007-9\n                                5. Kolb M, Collard HR: Staging of idiopathic pulmonary fibrosis: past, present and\n                                future. Eur Respir Rev. 2014, 23:220-224. 10.1183/09059180.00002114\n                                6. Pleasants R, Tighe RM: Management of Idiopathic Pulmonary Fibrosis. Ann Pharmacother.\n                                2019, 53:1238-1248. 10.1177/1060028019862497\n                                7. Pulmonary fibrosis. (2021). Accessed: 24 July 2023:\n                                https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis.\n                                8. Vainshelboim B: Exercise training in idiopathic pulmonary fibrosis: is it of\n                                benefit?. Breathe (Sheff). 2016, 12:130-8. 10.1183/20734735.006916\n                                9. Swigris JJ, Brown KK, Make BJ, Wamboldt FS: Pulmonary rehabilitation in idiopathic\n                                pulmonary fibrosis: a call for continued investigation. Respir Med. 2008, 102:1675-80.\n                                10.1016/j.rmed.2008.08.014\n                                10. Shariat C, Garvey C, Rigler J, Collard HR: Pulmonary rehabilitation improves\n                                functional capacity in patients with interstitial lung disease. Chest. 2007, 132:458.\n                                10.1378/chest.132.4_MeetingAbstracts.458\n                                11. Dowman L, Hill CJ, May A, Holland AE: Pulmonary rehabilitation for interstitial lung\n                                disease. Cochrane Database Syst Rev. 2021, 2:CD006322.\n                                10.1002/14651858.CD006322.pub4\n                                12. Naji N, Connor M, Donnelly S, et al.: Effectiveness of Pulmonary Rehabilitation in\n                                Restrictive Lung Disease. J Cardiopulm Rehabil. 2006, 26:237-43.\n                                10.1097/00008483-200607000-00007\n                                13. Cheng L, Tan B, Yin Y, et al.: Short- and long-term effects of pulmonary\n                                rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.\n                                Clini Rehabil. 2018, 32:1299-1307. 10.1177/0269215518779122\n                                14. Arnold MT, Dolezal BA, Cooper CB: Pulmonary Rehabilitation for Chronic Obstructive\n                                Pulmonary Disease: Highly Effective but Often Overlooked. Tuberc Respir Dis (Seoul).\n                                2020, 83:257-267. 10.4046/trd.2020.0064\n                                15. Liu W, Mu X, Wang X, Zhang P, Zhao L, Li Q: Effects of comprehensive pulmonary\n                                rehabilitation therapy on pulmonary functions and blood gas indexes of patients with\n                                severe pneumonia. Exp Ther Med. 2018, 16:1953-1957. 10.3892/etm.2018.6396\n                                16. Mahler B, Croitoru A: Pulmonary rehabilitation and tuberculosis: a new approach for\n                                an old disease.. Pneumologia. 2019, 68:107-113. 10.2478/pneum-2019-0024",
        "researchers": [
          ": Greenberg",
          "S.",
          "Moriarty",
          "S.",
          "Perera",
          "I.",
          "Kasper",
          "H.",
          "Kasper",
          "B.",
          "Moriarty",
          "H."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research--bQsrIkurMDc9xbk0kQdI",
      "data": {
        "_createdAt": "2025-06-04T16:58:27Z",
        "_id": "research--bQsrIkurMDc9xbk0kQdI",
        "_rev": "0R95WGIfgjXsgEpFfwHheI",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:27Z",
        "category": "case-report",
        "content": [
          {
            "_key": "asFIGz-prXOZj9yukon0I",
            "_type": "block",
            "children": [
              {
                "_key": "b0B3TGYF3Wt75OlEe1SwA",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "_OFseup6jHWQO5gzqG3yS",
            "_type": "block",
            "children": [
              {
                "_key": "tjJyaBLjgIlioDxTAl2Ah",
                "_type": "span",
                "marks": [],
                "text": "Neonatal Diabetes Mellitus (NDM) is a rare medical disease, with prevalence of 1 in\n                                90,000 to 160,000 live births, with 31% of all preterm disease linked to monogenic\n                                causes. The disease is further differentiated into transient and permanent NDM. 40% of\n                                patients diagnosed with NDM are responsive to oral sulfonylureas (SU) due to expressed\n                                mutations of the ABCC8 or KCNJ11 genes, coding for potassium adenosine triphosphate\n                                (K-ATP) channels in the pancreatic ꞵ cells. SUs bind to the sulfonylurea receptor 1\n                                (SUR1) subunit, closing the K-ATP channel and increasing the secretion of insulin from\n                                pancreatic ꞵ cells. Although SUs remain the mainstay of NDM treatment, these medications\n                                are traditionally only dosed and approved for hyperglycemic control in adults. Current\n                                treatment regimens suggest a high dose, 1 mg/kg/day, for patients with KCNJ11 neonatal\n                                diabetes.\n                                Our male neonate was born at 27 weeks via emergency cesarean section due to complete\n                                placenta previa and hemorrhage following perinatal betamethasone administration.\n                                Neonatal resuscitation was required for Apgars 3, 6, and 7 (at 1, 5, and 10-minutes\n                                respectively). During resuscitation, the patient was intubated and found to be\n                                hyperglycemic. He was subsequently started on Regular Humulin at 0.1 units/kg/dose\n                                subcutaneously (SQ) and increased to 0.2 units/kg/dose SQ before transfer to our\n                                facility. In our Neonatal Intensive Care Unit (NICU), the patient was kept on an insulin\n                                drip due to the small dose of SQ insulin necessary to cover for the patient's small\n                                bolus feed amounts. Meanwhile, the patient's genetic testing returned and he was found\n                                to be positive for the KCNJ11 NDM gene. He was slowly transitioned to oral feeds and\n                                started on glyburide. The patient failed his first glyburide wean but was successfully\n                                weaned on his second attempt and found to be euglycemic (blood glucose less than 200)\n                                prior to discharge home.\n                                This case report describes the unique and complicated clinical course of a premature\n                                neonate with an initially undifferentiated class of NDM requiring a microdose approach\n                                to both insulin and SU-based management. This report offers a concise recount of the\n                                applied diagnostic and therapeutic procedures. These lessons may be applied in the\n                                future for potential NDM cases. The authors received patient guardian consent to use\n                                their data for this report."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "wq-1NaEdwQ21QIJWAALBO",
            "_type": "block",
            "children": [
              {
                "_key": "9RZUu44L18jU6CqhL3rvP",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "APQTLtBqxBNrR1W41-jwN",
            "_type": "block",
            "children": [
              {
                "_key": "wnvH7qxgHt_oGK7LM7i8i",
                "_type": "span",
                "marks": [],
                "text": "1. Lemelman MB, Letourneau L, Greeley SA. Neonatal diabetes mellitus. Clinics in\n                                Perinatology. 2018;45(1):41–59. doi:10.1016/j.clp.2017.10.006 \n                                2. Beltrand J, Busiah K, Vaivre-Douret L, Fauret AL, Berdugo M, Cavé H, et al. Neonatal\n                                diabetes mellitus. Frontiers in Pediatrics. 2020;8. doi:10.3389/fped.2020.540718\n                                \n                                3. Madani H. Study of KCNJ11 gene mutations in association with monogenic diabetes of\n                                infancy and response to sulfonylurea treatment in a cohort study in Egypt. Acta\n                                Endocrinologica (Bucharest). 2016;12(2):157–60. doi:10.4183/aeb.2016.157 \n                                4. Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS.\n                                KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. Journal of Diabetes\n                                Research. 2015;2015:1–9. doi:10.1155/2015/908152 \n                                5. Wu B, Xu W. Case report: Neonatal diabetes mellitus caused by KCNJ11 mutation\n                                presenting with intracranial hemorrhage. Frontiers in Neurology. 2023;14.\n                                doi:10.3389/fneur.2023.1072078 \n                                6. Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, et al. Sulfonylurea\n                                treatment before genetic testing in neonatal diabetes: Pros and cons. The Journal of\n                                Clinical Endocrinology & Metabolism. 2014;99(12). doi:10.1210/jc.2014-2494 \n                                7. Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, et al.\n                                Effectiveness and safety of long-term treatment with sulfonylureas in patients with\n                                neonatal diabetes due to KCNJ11 mutations: An international cohort study. The Lancet\n                                Diabetes & Endocrinology. 2018;6(8):637–46. doi:10.1016/s2213-8587(18)30106-2\n                                \n                                8. Dahl A, Kumar S. Recent advances in neonatal diabetes. Diabetes, Metabolic Syndrome\n                                and Obesity: Targets and Therapy. 2020;Volume 13:355–64. doi:10.2147/dmso.s198932\n                                \n                                9. Garcin L, Mericq V, Fauret‐Amsellem A, Cave H, Polak M, Beltrand J. Neonatal diabetes\n                                due to potassium channel mutation: Response to sulfonylurea according to the genotype.\n                                Pediatric Diabetes. 2020;21(6):932–41. doi:10.1111/pedi.13041 \n                                10. Zhang H, Zhong X, Huang Z, Huang C, Liu T, Qiu Y. Sulfonylurea for the treatment of\n                                neonatal diabetes owing to KATP-channel mutations: A systematic review and\n                                meta-analysis. Oncotarget. 2017;8(64):108274–85. doi:10.18632/oncotarget.22548 \n                                11. Ashcroft F. Mechanisms of the glycaemic effects of sulfonylureas. Hormone and\n                                Metabolic Research. 1996;28(09):456–63. doi:10.1055/s-2007-979837"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Neonatal Diabetes Mellitus (NDM) is a rare medical disease, with prevalence of 1 in\n                                90,000 to 160,000 live births, with 31% of all preterm disease linked to monogenic\n                                causes. The disease is further differentiated into transient and perm...",
        "publishedAt": "2025-06-04T16:58:27.362Z",
        "references": "1. Lemelman MB, Letourneau L, Greeley SA. Neonatal diabetes mellitus. Clinics in\n                                Perinatology. 2018;45(1):41–59. doi:10.1016/j.clp.2017.10.006 \n                                2. Beltrand J, Busiah K, Vaivre-Douret L, Fauret AL, Berdugo M, Cavé H, et al. Neonatal\n                                diabetes mellitus. Frontiers in Pediatrics. 2020;8. doi:10.3389/fped.2020.540718\n                                \n                                3. Madani H. Study of KCNJ11 gene mutations in association with monogenic diabetes of\n                                infancy and response to sulfonylurea treatment in a cohort study in Egypt. Acta\n                                Endocrinologica (Bucharest). 2016;12(2):157–60. doi:10.4183/aeb.2016.157 \n                                4. Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS.\n                                KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. Journal of Diabetes\n                                Research. 2015;2015:1–9. doi:10.1155/2015/908152 \n                                5. Wu B, Xu W. Case report: Neonatal diabetes mellitus caused by KCNJ11 mutation\n                                presenting with intracranial hemorrhage. Frontiers in Neurology. 2023;14.\n                                doi:10.3389/fneur.2023.1072078 \n                                6. Carmody D, Bell CD, Hwang JL, Dickens JT, Sima DI, Felipe DL, et al. Sulfonylurea\n                                treatment before genetic testing in neonatal diabetes: Pros and cons. The Journal of\n                                Clinical Endocrinology & Metabolism. 2014;99(12). doi:10.1210/jc.2014-2494 \n                                7. Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, et al.\n                                Effectiveness and safety of long-term treatment with sulfonylureas in patients with\n                                neonatal diabetes due to KCNJ11 mutations: An international cohort study. The Lancet\n                                Diabetes & Endocrinology. 2018;6(8):637–46. doi:10.1016/s2213-8587(18)30106-2\n                                \n                                8. Dahl A, Kumar S. Recent advances in neonatal diabetes. Diabetes, Metabolic Syndrome\n                                and Obesity: Targets and Therapy. 2020;Volume 13:355–64. doi:10.2147/dmso.s198932\n                                \n                                9. Garcin L, Mericq V, Fauret‐Amsellem A, Cave H, Polak M, Beltrand J. Neonatal diabetes\n                                due to potassium channel mutation: Response to sulfonylurea according to the genotype.\n                                Pediatric Diabetes. 2020;21(6):932–41. doi:10.1111/pedi.13041 \n                                10. Zhang H, Zhong X, Huang Z, Huang C, Liu T, Qiu Y. Sulfonylurea for the treatment of\n                                neonatal diabetes owing to KATP-channel mutations: A systematic review and\n                                meta-analysis. Oncotarget. 2017;8(64):108274–85. doi:10.18632/oncotarget.22548 \n                                11. Ashcroft F. Mechanisms of the glycaemic effects of sulfonylureas. Hormone and\n                                Metabolic Research. 1996;28(09):456–63. doi:10.1055/s-2007-979837",
        "researchers": [
          ": Perera",
          "I.",
          "Sherwood",
          "B.",
          "Jensen",
          "B.",
          "Legard",
          "C.",
          "Patel",
          "H."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-9-8Pjem9Z1MCyr0XxKfIf",
      "data": {
        "_createdAt": "2025-06-04T16:58:28Z",
        "_id": "research-9-8Pjem9Z1MCyr0XxKfIf",
        "_rev": "5oPq5aauNY6lHJUDW4pf5h",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:28Z",
        "category": "project",
        "content": [
          {
            "_key": "BhRZ_DLzfA1LKEk4r82P4",
            "_type": "block",
            "children": [
              {
                "_key": "ugKs0KccXKj0zRXjk8Ohs",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "EYbbEegPG_93BReApIK2p",
            "_type": "block",
            "children": [
              {
                "_key": "fPFdhvUugE0SqjnCBftqK",
                "_type": "span",
                "marks": [],
                "text": "Current literature demonstrates the highest prevalence of prostate cancer among black\n                                men in the United States. According to the American Cancer Society, in American men,\n                                prostate cancer is the second leading cause of cancer death following lung cancer, most\n                                commonly metastasizing to the bones and lymph nodes. Data indicates that black patients\n                                are disproportionately affected by prostate cancer, suffering from higher rates of\n                                aggressive and metastatic disease and higher mortality rates. Risk factors for prostate\n                                cancer, although some still debated, include diet, exercise, cigarette smoking and\n                                obesity. These potential risk factors within this population may be attributed to, but\n                                not limited to, minority populations disproportionately affected by food deserts, food\n                                swamps, and unemployment. Furthermore, research has demonstrated black patients are more\n                                likely to experience delayed treatment, underutilization of treatments, poor\n                                interactions with physicians and longer referral times when compared to other racial and\n                                ethnic groups. Beyond psychosocial factors, biologic factors such as genetics, have a\n                                potential role for utility in screening and treatments. The goal of this study is to\n                                review the 2020 Surveillance, Epidemiology and End Results (SEER) results and review\n                                literature to improve the current understanding of prostate cancer risk factors."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "c1rVK8CJidrT-YIO6Mc17",
            "_type": "block",
            "children": [
              {
                "_key": "PYHcbvPv4G3H8Y0UhsvLJ",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "LEO4lyZ_HSp_d3XhQDgid",
            "_type": "block",
            "children": [
              {
                "_key": "k79NTGjJqz1HC2KJD6kA8",
                "_type": "span",
                "marks": [],
                "text": "1. Key statistics for prostate cancer. (2024, January 19).\n                                https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html\n                                2. Rawla, P. (2019). Epidemiology of Prostate Cancer. World Journal of Oncology, 10(2),\n                                63–89.\n                                3. Fletcher, S. A., Marchese, M., Cole, A. P., Mahal, B. A., Friedlander, D. F.,\n                                Krimphove, M., Kilbridge, K. L., Lipsitz, S. R., Nguyen, P. L., Choueiri, T. K., Kibel,\n                                A. S., & Trinh, Q.-D. (2020). Geographic Distribution of Racial Differences in Prostate\n                                Cancer Mortality. JAMA Network Open, 3(3), e201839.\n                                4. Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R.\n                                L. (2022). Cancer statistics for African American/Black People 2022. CA: A Cancer\n                                Journal for Clinicians, 72(3), 202–229.\n                                5. Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W., Alumkal, J. J., Beer, T. M.,\n                                Beltran, H., George, D. J., Heath, E. I., Higano, C. S., McKay, R. R., Morgans, A. K.,\n                                Patnaik, A., Ryan, C. J., Schaeffer, E. M., Stadler, W. M., Taplin, M.-E., Kauff, N. D.,\n                                Vinson, J., … Cheng, H. H. (2018). Evolving Intersection Between Inherited Cancer\n                                Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the\n                                Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO\n                                Precision Oncology, 2018. https://doi.org/10.1200/PO.18.00060\n                                6. Johnson, J. R., Woods-Burnham, L., Hooker, S. E., Jr, Batai, K., & Kittles, R. A.\n                                (2021). Genetic Contributions to Prostate Cancer Disparities in Men of West African\n                                Descent. Frontiers in Oncology, 11, 770500.\n                                7. Krimphove, M. J., Cole, A. P., Fletcher, S. A., Harmouch, S. S., Berg, S., Lipsitz,\n                                S. R., Sun, M., Nabi, J., Nguyen, P. L., Hu, J. C., Kibel, A. S., Choueiri, T. K.,\n                                Kluth, L. A., & Trinh, Q.-D. (2019). Evaluation of the contribution of demographics,\n                                access to health care, treatment, and tumor characteristics to racial differences in\n                                survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 22(1),\n                                125–136.\n                                8. Matsushita, M., Fujita, K., & Nonomura, N. (2020). Influence of Diet and Nutrition on\n                                Prostate Cancer. International Journal of Molecular Sciences, 21(4).\n                                https://doi.org/10.3390/ijms21041447\n                                9. SEER*Explorer. (n.d.). Retrieved January 24, 2024, from\n                                https://seer.cancer.gov/statistics-network/explorer/application.html?site=66&data_type=2&graph_type=2&compareBy=race&chk_race_6=6&chk_race_5=5&chk_race_4=4&chk_race_9=9&chk_race_2=2&hdn_sex=2&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2\n                                10. Lawrence, W. R., McGee-Avila, J. K., Vo, J. B., Luo, Q., Chen, Y., Inoue-Choi, M.,\n                                Berrington de González, A., Freedman, N. D., & Shiels, M. S. (2022). Trends in Cancer\n                                Mortality Among Black Individuals in the US From 1999 to 2019. JAMA Oncology, 8(8),\n                                1184–1189.\n                                11. Wu, I., & Modlin, C. S. (2012). Disparities in prostate cancer in African American\n                                men: what primary care physicians can do. Cleveland Clinic Journal of Medicine, 79(5),\n                                313–320.\n                                12. Parikh, R. B., Gallo, J. J., Wong, Y.-N., Robinson, K. W., Cashy, J. P., Narayan,\n                                V., Jayadevappa, R., & Chhatre, S. (2021). Long-term depression incidence and associated\n                                mortality among African American and White prostate cancer survivors. Cancer, 127(18),\n                                3476–3485.\n                                13. Dinh, K. T., Reznor, G., Muralidhar, V., Mahal, B. A., Nezolosky, M. D., Choueiri,\n                                T. K., Hoffman, K. E., Hu, J. C., Sweeney, C. J., Trinh, Q.-D., & Nguyen, P. L. (2016).\n                                Association of Androgen Deprivation Therapy With Depression in Localized Prostate\n                                Cancer. Journal of Clinical Oncology: Official Journal of the American Society of\n                                Clinical Oncology, 34(16), 1905–1912.\n                                14. Lin, P.-H., Liu, J.-M., Hsu, R.-J., Chuang, H.-C., Chang, S.-W., Pang, S.-T., Chang,\n                                Y.-H., Chuang, C.-K., & Lin, S.-K. (2018). Depression Negatively Impacts Survival of\n                                Patients with Metastatic Prostate Cancer. International Journal of Environmental\n                                Research and Public Health, 15(10). https://doi.org/10.3390/ijerph15102148\n                                15. Campbell, L. C., Keefe, F. J., McKee, D. C., Edwards, C. L., Herman, S. H., Johnson,\n                                L. E., Colvin, O. M., McBride, C. M., & Donattuci, C. F. (2004). Prostate cancer in\n                                African Americans: relationship of patient and partner self-efficacy to quality of life.\n                                Journal of Pain and Symptom Management, 28(5), 433–444.\n                                16. Pietro, G. D., Chornokur, G., Kumar, N. B., Davis, C., & Park, J. Y. (2016). Racial\n                                Differences in the Diagnosis and Treatment of Prostate Cancer. International\n                                Neurourology Journal, 20(Suppl 2), S112–S119.\n                                17. Lowder, D., Rizwan, K., McColl, C., Paparella, A., Ittmann, M., Mitsiades, N., &\n                                Kaochar, S. (2022). Racial disparities in prostate cancer: A complex interplay between\n                                socioeconomic inequities and genomics. Cancer Letters, 531, 71–82.\n                                18. Press, D. J., Shariff-Marco, S., Lichtensztajn, D. Y., Lauderdale, D., Murphy, A.\n                                B., Inamdar, P. P., DeRouen, M. C., Hamilton, A. S., Yang, J., Lin, K., Hedeker, D.,\n                                Haiman, C. A., Cheng, I., & Gomez, S. L. (2022). Contributions of Social Factors to\n                                Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men\n                                with Prostate Cancer in California. Cancer Epidemiology, Biomarkers & Prevention: A\n                                Publication of the American Association for Cancer Research, Cosponsored by the American\n                                Society of Preventive Oncology, 31(2), 404–412.\n                                19. Cooksey Stowers, K., Jiang, Q., Atoloye, A., Lucan, S., & Gans, K. (2020). Racial\n                                Differences in Perceived Food Swamp and Food Desert Exposure and Disparities in\n                                Self-Reported Dietary Habits. International Journal of Environmental Research and Public\n                                Health, 17(19). https://doi.org/10.3390/ijerph17197143\n                                20. Wang, Y., & Chen, X. (2011). How much of racial/ethnic disparities in dietary\n                                intakes, exercise, and weight status can be explained by nutrition- and health-related\n                                psychosocial factors and socioeconomic status among US adults? Journal of the American\n                                Dietetic Association, 111(12), 1904–1911.\n                                21. Ghosh-Dastidar, B., Cohen, D., Hunter, G., Zenk, S. N., Huang, C., Beckman, R., &\n                                Dubowitz, T. (2014). Distance to store, food prices, and obesity in urban food deserts.\n                                American Journal of Preventive Medicine, 47(5), 587–595.\n                                22. Bancroft, E. K., Raghallaigh, H. N., Page, E. C., & Eeles, R. A. (2021). Updates in\n                                Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Current\n                                Genetic Medicine Reports, 9(4), 47–58.\n                                23. Castro, E., & Eeles, R. (2012). The role of BRCA1 and BRCA2 in prostate cancer.\n                                Asian Journal of Andrology, 14(3), 409–414.\n                                24. Adhyam, M., & Gupta, A. K. (2012). A Review on the Clinical Utility of PSA in Cancer\n                                Prostate. Indian Journal of Surgical Oncology, 3(2), 120–129.\n                                25. Shenoy, D., Packianathan, S., Chen, A. M., & Vijayakumar, S. (2016). Do\n                                African-American men need separate prostate cancer screening guidelines? BMC Urology,\n                                16(1), 19.\n                                26. Powell, I. J., Vigneau, F. D., Bock, C. H., Ruterbusch, J., & Heilbrun, L. K.\n                                (2014). Reducing prostate cancer racial disparity: evidence for aggressive early\n                                prostate cancer PSA testing of African American men. Cancer Epidemiology, Biomarkers &\n                                Prevention: A Publication of the American Association for Cancer Research, Cosponsored\n                                by the American Society of Preventive Oncology, 23(8), 1505–1511."
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Current literature demonstrates the highest prevalence of prostate cancer among black\n                                men in the United States. According to the American Cancer Society, in American men,\n                                prostate cancer is the second leading cause of cancer death follo...",
        "publishedAt": "2025-06-04T16:58:28.388Z",
        "references": "1. Key statistics for prostate cancer. (2024, January 19).\n                                https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html\n                                2. Rawla, P. (2019). Epidemiology of Prostate Cancer. World Journal of Oncology, 10(2),\n                                63–89.\n                                3. Fletcher, S. A., Marchese, M., Cole, A. P., Mahal, B. A., Friedlander, D. F.,\n                                Krimphove, M., Kilbridge, K. L., Lipsitz, S. R., Nguyen, P. L., Choueiri, T. K., Kibel,\n                                A. S., & Trinh, Q.-D. (2020). Geographic Distribution of Racial Differences in Prostate\n                                Cancer Mortality. JAMA Network Open, 3(3), e201839.\n                                4. Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R.\n                                L. (2022). Cancer statistics for African American/Black People 2022. CA: A Cancer\n                                Journal for Clinicians, 72(3), 202–229.\n                                5. Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W., Alumkal, J. J., Beer, T. M.,\n                                Beltran, H., George, D. J., Heath, E. I., Higano, C. S., McKay, R. R., Morgans, A. K.,\n                                Patnaik, A., Ryan, C. J., Schaeffer, E. M., Stadler, W. M., Taplin, M.-E., Kauff, N. D.,\n                                Vinson, J., … Cheng, H. H. (2018). Evolving Intersection Between Inherited Cancer\n                                Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the\n                                Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO\n                                Precision Oncology, 2018. https://doi.org/10.1200/PO.18.00060\n                                6. Johnson, J. R., Woods-Burnham, L., Hooker, S. E., Jr, Batai, K., & Kittles, R. A.\n                                (2021). Genetic Contributions to Prostate Cancer Disparities in Men of West African\n                                Descent. Frontiers in Oncology, 11, 770500.\n                                7. Krimphove, M. J., Cole, A. P., Fletcher, S. A., Harmouch, S. S., Berg, S., Lipsitz,\n                                S. R., Sun, M., Nabi, J., Nguyen, P. L., Hu, J. C., Kibel, A. S., Choueiri, T. K.,\n                                Kluth, L. A., & Trinh, Q.-D. (2019). Evaluation of the contribution of demographics,\n                                access to health care, treatment, and tumor characteristics to racial differences in\n                                survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 22(1),\n                                125–136.\n                                8. Matsushita, M., Fujita, K., & Nonomura, N. (2020). Influence of Diet and Nutrition on\n                                Prostate Cancer. International Journal of Molecular Sciences, 21(4).\n                                https://doi.org/10.3390/ijms21041447\n                                9. SEER*Explorer. (n.d.). Retrieved January 24, 2024, from\n                                https://seer.cancer.gov/statistics-network/explorer/application.html?site=66&data_type=2&graph_type=2&compareBy=race&chk_race_6=6&chk_race_5=5&chk_race_4=4&chk_race_9=9&chk_race_2=2&hdn_sex=2&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2\n                                10. Lawrence, W. R., McGee-Avila, J. K., Vo, J. B., Luo, Q., Chen, Y., Inoue-Choi, M.,\n                                Berrington de González, A., Freedman, N. D., & Shiels, M. S. (2022). Trends in Cancer\n                                Mortality Among Black Individuals in the US From 1999 to 2019. JAMA Oncology, 8(8),\n                                1184–1189.\n                                11. Wu, I., & Modlin, C. S. (2012). Disparities in prostate cancer in African American\n                                men: what primary care physicians can do. Cleveland Clinic Journal of Medicine, 79(5),\n                                313–320.\n                                12. Parikh, R. B., Gallo, J. J., Wong, Y.-N., Robinson, K. W., Cashy, J. P., Narayan,\n                                V., Jayadevappa, R., & Chhatre, S. (2021). Long-term depression incidence and associated\n                                mortality among African American and White prostate cancer survivors. Cancer, 127(18),\n                                3476–3485.\n                                13. Dinh, K. T., Reznor, G., Muralidhar, V., Mahal, B. A., Nezolosky, M. D., Choueiri,\n                                T. K., Hoffman, K. E., Hu, J. C., Sweeney, C. J., Trinh, Q.-D., & Nguyen, P. L. (2016).\n                                Association of Androgen Deprivation Therapy With Depression in Localized Prostate\n                                Cancer. Journal of Clinical Oncology: Official Journal of the American Society of\n                                Clinical Oncology, 34(16), 1905–1912.\n                                14. Lin, P.-H., Liu, J.-M., Hsu, R.-J., Chuang, H.-C., Chang, S.-W., Pang, S.-T., Chang,\n                                Y.-H., Chuang, C.-K., & Lin, S.-K. (2018). Depression Negatively Impacts Survival of\n                                Patients with Metastatic Prostate Cancer. International Journal of Environmental\n                                Research and Public Health, 15(10). https://doi.org/10.3390/ijerph15102148\n                                15. Campbell, L. C., Keefe, F. J., McKee, D. C., Edwards, C. L., Herman, S. H., Johnson,\n                                L. E., Colvin, O. M., McBride, C. M., & Donattuci, C. F. (2004). Prostate cancer in\n                                African Americans: relationship of patient and partner self-efficacy to quality of life.\n                                Journal of Pain and Symptom Management, 28(5), 433–444.\n                                16. Pietro, G. D., Chornokur, G., Kumar, N. B., Davis, C., & Park, J. Y. (2016). Racial\n                                Differences in the Diagnosis and Treatment of Prostate Cancer. International\n                                Neurourology Journal, 20(Suppl 2), S112–S119.\n                                17. Lowder, D., Rizwan, K., McColl, C., Paparella, A., Ittmann, M., Mitsiades, N., &\n                                Kaochar, S. (2022). Racial disparities in prostate cancer: A complex interplay between\n                                socioeconomic inequities and genomics. Cancer Letters, 531, 71–82.\n                                18. Press, D. J., Shariff-Marco, S., Lichtensztajn, D. Y., Lauderdale, D., Murphy, A.\n                                B., Inamdar, P. P., DeRouen, M. C., Hamilton, A. S., Yang, J., Lin, K., Hedeker, D.,\n                                Haiman, C. A., Cheng, I., & Gomez, S. L. (2022). Contributions of Social Factors to\n                                Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men\n                                with Prostate Cancer in California. Cancer Epidemiology, Biomarkers & Prevention: A\n                                Publication of the American Association for Cancer Research, Cosponsored by the American\n                                Society of Preventive Oncology, 31(2), 404–412.\n                                19. Cooksey Stowers, K., Jiang, Q., Atoloye, A., Lucan, S., & Gans, K. (2020). Racial\n                                Differences in Perceived Food Swamp and Food Desert Exposure and Disparities in\n                                Self-Reported Dietary Habits. International Journal of Environmental Research and Public\n                                Health, 17(19). https://doi.org/10.3390/ijerph17197143\n                                20. Wang, Y., & Chen, X. (2011). How much of racial/ethnic disparities in dietary\n                                intakes, exercise, and weight status can be explained by nutrition- and health-related\n                                psychosocial factors and socioeconomic status among US adults? Journal of the American\n                                Dietetic Association, 111(12), 1904–1911.\n                                21. Ghosh-Dastidar, B., Cohen, D., Hunter, G., Zenk, S. N., Huang, C., Beckman, R., &\n                                Dubowitz, T. (2014). Distance to store, food prices, and obesity in urban food deserts.\n                                American Journal of Preventive Medicine, 47(5), 587–595.\n                                22. Bancroft, E. K., Raghallaigh, H. N., Page, E. C., & Eeles, R. A. (2021). Updates in\n                                Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Current\n                                Genetic Medicine Reports, 9(4), 47–58.\n                                23. Castro, E., & Eeles, R. (2012). The role of BRCA1 and BRCA2 in prostate cancer.\n                                Asian Journal of Andrology, 14(3), 409–414.\n                                24. Adhyam, M., & Gupta, A. K. (2012). A Review on the Clinical Utility of PSA in Cancer\n                                Prostate. Indian Journal of Surgical Oncology, 3(2), 120–129.\n                                25. Shenoy, D., Packianathan, S., Chen, A. M., & Vijayakumar, S. (2016). Do\n                                African-American men need separate prostate cancer screening guidelines? BMC Urology,\n                                16(1), 19.\n                                26. Powell, I. J., Vigneau, F. D., Bock, C. H., Ruterbusch, J., & Heilbrun, L. K.\n                                (2014). Reducing prostate cancer racial disparity: evidence for aggressive early\n                                prostate cancer PSA testing of African American men. Cancer Epidemiology, Biomarkers &\n                                Prevention: A Publication of the American Association for Cancer Research, Cosponsored\n                                by the American Society of Preventive Oncology, 23(8), 1505–1511.",
        "researchers": [
          ": Yeckley",
          "M.",
          "Sabbagh",
          "M.",
          "Santiago",
          "M.",
          "Moriarty",
          "S.",
          "Santiago",
          "R.",
          "Patel",
          "J.",
          "Peddibhotla",
          "V.",
          "Perera",
          "I.",
          "Rawlins II",
          "F."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-aepOOvQLx8k5BFrZKl1Rq",
      "data": {
        "_createdAt": "2025-06-04T16:58:29Z",
        "_id": "research-aepOOvQLx8k5BFrZKl1Rq",
        "_rev": "5oPq5aauNY6lHJUDW4pfAj",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:29Z",
        "category": "project",
        "content": [
          {
            "_key": "uCd_11jstcbS4G_mVHixF",
            "_type": "block",
            "children": [
              {
                "_key": "xcwzMpUuk4TAp9qiPaInP",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "SmmKYdffpYxi_isL3e_di",
            "_type": "block",
            "children": [
              {
                "_key": "Pwo10tRega6RrDn2JTjGi",
                "_type": "span",
                "marks": [],
                "text": "In 2021, the opioid epidemic in Virginia recorded its highest death toll to date, 2229\n                                deaths. The first three quarters of 2022 totaled 1579 deaths. Concomitantly, states have\n                                begun the introduction of Good Samaritan Laws and naloxone distribution programs. A 2014\n                                national study of 30 states with naloxone distribution programs found that these\n                                programs resulted in a 14% lower overdose rate when compared to states without similar\n                                programs. The Edward Via College of Osteopathic Medicine Virginia Campus (VCOM-VC)\n                                Overdose Prevention Task Force (OPTF) has committed to training each incoming first-year\n                                medical student in naloxone administration using REVIVE!. REVIVE! is the Commonwealth of\n                                Virginia’s standardized Opioid Overdose and Naloxone Education (OONE) program, designed\n                                to educate participants in the recognition and response protocol for an opioid overdose\n                                emergency. This is the fourth year of successfully training 100% of the first-year class\n                                at VCOM-VC. Students who have participated in these programs become certified by the\n                                Virginia Department of Health to administer naloxone. This training is standardized and\n                                delivered by agents appointed by the state of Virginia; however, the program lacks\n                                peer-reviewed evaluation of its objectives: 1. Understand the REVIVE! program and\n                                legislation, 2. Understand addiction, 3. Understand how opioid overdose emergencies\n                                happen and how to recognize them, 4. Understand how naloxone works, 5. Identify risk\n                                factors that may make someone more susceptible to an opioid overdose emergency, 6.\n                                Dispel common myths about how to reverse an opioid overdose, and 7. Learn how to respond\n                                to an opioid overdose emergency with the administration of naloxone. Students who\n                                complete this training are not evaluated for their competency in the listed objectives.\n                                This prospective cohort study compares the effectiveness of the didactic REVIVE! course\n                                to a REVIVE! course plus simulation-based training. Simulation has been shown to improve\n                                student comfort and performance in procedural skills while emphasizing teamwork and\n                                communication. The study seeks to elucidate the effectiveness of the course via a\n                                standardized post-assessment, simulated assessment of the participant’s ability to\n                                recognize and implement the REVIVE! protocol, and evaluation of 6-month retention. This\n                                study is currently in the initial data analysis phase as approved by the VCOM IRB,\n                                protocol number 2023-132."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "MjPPOJTshh9gTlQgxYFm2",
            "_type": "block",
            "children": [
              {
                "_key": "kidZD6MfJkfIUlsWhFWFT",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "OHMZ69xY66R2qUIzNXGSC",
            "_type": "block",
            "children": [
              {
                "_key": "wHk4NfmpgKXjVSWFGOkoA",
                "_type": "span",
                "marks": [],
                "text": "1. Declaration of Public Health Emergency. Virginia Department of Health. Published\n                                November 21, 2016. Accessed November 14, 2023.\n                                https://www.vdh.virginia.gov/commissioner/declaration-of-public-health-emergency/\n                                2. REVIVE! Opioid Overdose and Naloxone Education (OONE) program for the Commonwealth of\n                                Virginia. Virginia Department of Behavioral Health and Development Services. 2023.\n                                Accessed December 8, 2023.\n                                https://dbhds.virginia.gov/behavioral-health/substance-abuse-services/revive/\n                                3. Okuda, Y., Bryson, E. O., DeMaria, S., Jacobson, L., Quinones, J., Shen, B., &\n                                Levine, A. I. (2009). The utility of simulation in medical education: What is the\n                                evidence? Mount Sinai Journal of Medicine: A Journal of Translational and Personalized\n                                Medicine, 76(4), 330–343. https://doi.org/10.1002/msj.20127"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "In 2021, the opioid epidemic in Virginia recorded its highest death toll to date, 2229\n                                deaths. The first three quarters of 2022 totaled 1579 deaths. Concomitantly, states have\n                                begun the introduction of Good Samaritan Laws and naloxone d...",
        "publishedAt": "2025-06-04T16:58:29.393Z",
        "references": "1. Declaration of Public Health Emergency. Virginia Department of Health. Published\n                                November 21, 2016. Accessed November 14, 2023.\n                                https://www.vdh.virginia.gov/commissioner/declaration-of-public-health-emergency/\n                                2. REVIVE! Opioid Overdose and Naloxone Education (OONE) program for the Commonwealth of\n                                Virginia. Virginia Department of Behavioral Health and Development Services. 2023.\n                                Accessed December 8, 2023.\n                                https://dbhds.virginia.gov/behavioral-health/substance-abuse-services/revive/\n                                3. Okuda, Y., Bryson, E. O., DeMaria, S., Jacobson, L., Quinones, J., Shen, B., &\n                                Levine, A. I. (2009). The utility of simulation in medical education: What is the\n                                evidence? Mount Sinai Journal of Medicine: A Journal of Translational and Personalized\n                                Medicine, 76(4), 330–343. https://doi.org/10.1002/msj.20127",
        "researchers": [
          ": Shenk A.",
          "Gordon",
          "A.",
          "Nelson",
          "B.",
          "Perera",
          "I.",
          "Moomaw",
          "E.",
          "Johnston",
          "T.",
          "Tate",
          "W.",
          "Thommason",
          "A.",
          "D’Arpa",
          "E.",
          "Nguyen",
          "T.",
          "Anandakrishnan",
          "R.",
          "Martin",
          "R.",
          "Callahan",
          "C.",
          "Mahaney",
          "J."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-lxPwpB2g2PUWNLhxvVsfA",
      "data": {
        "_createdAt": "2025-06-04T16:58:30Z",
        "_id": "research-lxPwpB2g2PUWNLhxvVsfA",
        "_rev": "jfcORSZ86cdtiqyuKTPvrr",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:30Z",
        "category": "project",
        "content": [
          {
            "_key": "XVCyN653vf2a2qmenmYCq",
            "_type": "block",
            "children": [
              {
                "_key": "O00588gWne2N6E3eEHyDG",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "hhDUYBhcfdjtseCjLiAlb",
            "_type": "block",
            "children": [
              {
                "_key": "3WTedmjNL1-Kvo5mCD9np",
                "_type": "span",
                "marks": [],
                "text": "A tubo-ovarian abscess (TOA) is an infectious mass of the adnexa. This article presents\n                                a well-documented case of a 27-year-old female presenting to the emergency department\n                                with a TOA. Physical exam findings and an initial computed tomography scan (CT) with\n                                contrast revealed a right iliopsoas abscess, an inflammatory process in the right lower\n                                quadrant, later diagnosed as a TOA with the use of ultrasound (US) without a history of\n                                sexually transmitted infection (STI). The clinical decision tree utilized in this\n                                patient’s case highlights the importance of keeping a TOA high on the list of\n                                differential diagnoses while investigating appendicitis and other inflammatory\n                                pathologies in the lower abdomen."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "BXMNgRorTF0S8U3ZJmpKI",
            "_type": "block",
            "children": [
              {
                "_key": "nNWsn8Ld2WSWhXxJ3N5eU",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "Nu4tjpHXLjC-oDDfyJV3R",
            "_type": "block",
            "children": [
              {
                "_key": "4ofdHyD7G8dgIcETJ5bDE",
                "_type": "span",
                "marks": [],
                "text": "1. Kairys N, Roepke C: Tubo-Ovarian Abscess. StatPearls [Internet], StatPearls\n                                Publishing, Treasure Island, FL; 2023.\n                                2. Bridwell RE, Koyfman A, Long B: High risk and low prevalence diseases: tubo-ovarian\n                                abscess. Am J Emerg Med. 2022, 57:70-5. 10.1016/j.ajem.2022.04.026\n                                3. Gjelland K, Ekerhovd E, Granberg S: Transvaginal ultrasound-guided aspiration for\n                                treatment of tubo-ovarian abscess: a study of 302 cases. Am J Obstet Gynecol. 2005,\n                                193:1323-30. 10.1016/j.ajog.2005.06.019\n                                4. Reed SD, Landers DV, Sweet RL: Antibiotic treatment of tuboovarian abscess:\n                                comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens.\n                                Am J Obstet Gynecol. 1991, 164:1556-61; discussion 1561-2.\n                                10.1016/0002-9378(91)91436-z\n                                5. Tuboovarian abscess. (2021). Accessed: April 24, 2023:\n                                https://www.dynamed.com/condition/tuboovarian-abscess.\n                                6. Caporale N, Morselli-Labate AM, Nardi E, Cogliandro R, Cavazza M, Stanghellini V:\n                                Acute abdominal pain in the emergency department of a university hospital in Italy.\n                                United European Gastroenterol J. 2016, 4:297-304. 10.1177/2050640615606012\n                                7. Arvig MD, Mogensen CB, Skjøt-Arkil H, Johansen IS, Rosenvinge FS, Lassen AT: Chief\n                                complaints, underlying diagnoses, and mortality in adult, non-trauma emergency\n                                department visits: a population-based, multicenter cohort study. West J Emerg Med. 2022,\n                                23:855-63. 10.5811/westjem.2022.9.56332"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "A tubo-ovarian abscess (TOA) is an infectious mass of the adnexa. This article presents\n                                a well-documented case of a 27-year-old female presenting to the emergency department\n                                with a TOA. Physical exam findings and an initial computed tom...",
        "publishedAt": "2025-06-04T16:58:30.436Z",
        "references": "1. Kairys N, Roepke C: Tubo-Ovarian Abscess. StatPearls [Internet], StatPearls\n                                Publishing, Treasure Island, FL; 2023.\n                                2. Bridwell RE, Koyfman A, Long B: High risk and low prevalence diseases: tubo-ovarian\n                                abscess. Am J Emerg Med. 2022, 57:70-5. 10.1016/j.ajem.2022.04.026\n                                3. Gjelland K, Ekerhovd E, Granberg S: Transvaginal ultrasound-guided aspiration for\n                                treatment of tubo-ovarian abscess: a study of 302 cases. Am J Obstet Gynecol. 2005,\n                                193:1323-30. 10.1016/j.ajog.2005.06.019\n                                4. Reed SD, Landers DV, Sweet RL: Antibiotic treatment of tuboovarian abscess:\n                                comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens.\n                                Am J Obstet Gynecol. 1991, 164:1556-61; discussion 1561-2.\n                                10.1016/0002-9378(91)91436-z\n                                5. Tuboovarian abscess. (2021). Accessed: April 24, 2023:\n                                https://www.dynamed.com/condition/tuboovarian-abscess.\n                                6. Caporale N, Morselli-Labate AM, Nardi E, Cogliandro R, Cavazza M, Stanghellini V:\n                                Acute abdominal pain in the emergency department of a university hospital in Italy.\n                                United European Gastroenterol J. 2016, 4:297-304. 10.1177/2050640615606012\n                                7. Arvig MD, Mogensen CB, Skjøt-Arkil H, Johansen IS, Rosenvinge FS, Lassen AT: Chief\n                                complaints, underlying diagnoses, and mortality in adult, non-trauma emergency\n                                department visits: a population-based, multicenter cohort study. West J Emerg Med. 2022,\n                                23:855-63. 10.5811/westjem.2022.9.56332",
        "researchers": [
          ": Menendez",
          "S.",
          "Moriarty",
          "S.",
          "Perera",
          "I.",
          "Rawlins II",
          "F."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "research-eS_9GObqx2bDD5KS6d3O6",
      "data": {
        "_createdAt": "2025-06-04T16:58:31Z",
        "_id": "research-eS_9GObqx2bDD5KS6d3O6",
        "_rev": "0R95WGIfgjXsgEpFfwHhpy",
        "_type": "researchProject",
        "_updatedAt": "2025-06-04T16:58:31Z",
        "category": "original-research",
        "content": [
          {
            "_key": "oWU2xj75ewaP7o_MOmokG",
            "_type": "block",
            "children": [
              {
                "_key": "Pf9r30_Phlz516TRRmH1F",
                "_type": "span",
                "marks": [],
                "text": "Abstract"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "TS6mNvedW2pT-XG9SWKD7",
            "_type": "block",
            "children": [
              {
                "_key": "_2oSbE_nukLkgT5ffN5O_",
                "_type": "span",
                "marks": [],
                "text": "Traditionally, medical students have been evaluated on their performance and reporting\n                                of history and physical exam i n Standardized Patient experiences within the Hospital\n                                Integrated Clinical Cases (HICC) course to determine their mastery over the subject\n                                material. At the Edward Via College of Osteopathic Medicine (VCOM) students have always\n                                been evaluated on both their performance within the simulated patient encounter and\n                                their ability to properly\n                                document their Medical Decision Making (MDM). Recently, in accordance with the January\n                                1st, 2023, shift in CPT Evaluation and Management guidelines to focus on MDM and visit\n                                timing rather than history and physical exam, and the goal to produce medical students\n                                with dense medical lexicons, the VCOM Virginia Campus has begun evaluating students\n                                according to a pre-determined set of keywords, as established for their specific\n                                Standardized Patient case. (AMA) Our proprietary MDM Keyword Analyzer is able to\n                                accurately convert audio-based HPI presentations into textual input to analyze and\n                                provide feedback to students on their mastery of the medical lexicon and to determine\n                                critical criteria for MDM, such as New York Heart Association (NYHA) Class for\n                                standardized classification of heart failure symptoms. (Daniels et al., 2023) In\n                                continuation of this previous project and evolution of the concept, this study will\n                                discuss the use of a Voice Recognition-based System paired to the Random Forests\n                                analytical method. This system will be evaluated on its ability to assess medical\n                                student’s MDM based on pre-determined keywords in the setting of high fidelity medical\n                                simulations or Standardized Patient encounters while recognizing the many challenges to\n                                voice recognition, such as converted audio that is not clear or assessing an\n                                unstructured recording. (Quiroz et al., 2019) Specifically, recent analysis has found\n                                modern voice recognition models used in MDM carry a 7% error rate – meaning 7 out of\n                                every 100 auto-transcribed words contain a transcription error. (Zhou et al., 2018) This\n                                study’s purpose is to evaluate a Voice Recognition-based proprietary technique in its\n                                ability to assess medical student’s clinical decision making based on pre-determined\n                                keywords."
              }
            ],
            "markDefs": [],
            "style": "normal"
          },
          {
            "_key": "lfNpiKKlGNXlD0oHU7526",
            "_type": "block",
            "children": [
              {
                "_key": "oThiduAJbpztR0VoCw9yS",
                "_type": "span",
                "marks": [],
                "text": "References"
              }
            ],
            "markDefs": [],
            "style": "h2"
          },
          {
            "_key": "oePjZv1BOeSJor6ZeUp1d",
            "_type": "block",
            "children": [
              {
                "_key": "rZluCFo2F0jx0nE5kcl4Z",
                "_type": "span",
                "marks": [],
                "text": "1. American Medical Association. CPT® Evaluation and Management. American Medical\n                                Association.\n                                https://www.ama-assn.org/practice-management/cpt/cpt-evaluation-and-management.\n                                Published December 27, 2023. Accessed January 19, 2024.\n                                2. Commission on Osteopathic College Accreditation. Accreditation of Colleges of\n                                Osteopathic Medicine: COM Continuing Accreditation Standards. American Osteopathic\n                                Association; 2023.\n                                https://osteopathic.org/index.php?aam-media=/wp-content/uploads/COCA-2023-COM-Continuing-Standards.pdf.\n                                3. Goss FR, Blackley SV, Ortega CA, et al. A clinician survey of using speech\n                                recognition for clinical documentation in the electronic health record. Int J Med\n                                Inform. 2019;130:103938.\n                                4. Kauppinen T, Koivikko MP, Ahovuo J. Improvement of report workflow and productivity\n                                using speech recognition--a follow-up study. J Digit Imaging.\n                                2008;21(4):378-382.\n                                5. Radford, A., Kim, J. W., Xu, T., Brockman, G., McLeavey, C., & Sutskever, I.\n                                (2022). Robust Speech Recognition via Large-Scale Weak Supervision. ms, San\n                                Fransisco. \n                                6. Introducing whisper. Introducing Whisper. (n.d.).\n                                https://openai.com/research/whisper"
              }
            ],
            "markDefs": [],
            "style": "normal"
          }
        ],
        "description": "Traditionally, medical students have been evaluated on their performance and reporting\n                                of history and physical exam i n Standardized Patient experiences within the Hospital\n                                Integrated Clinical Cases (HICC) course to determine their mast...",
        "publishedAt": "2025-06-04T16:58:31.426Z",
        "references": "1. American Medical Association. CPT® Evaluation and Management. American Medical\n                                Association.\n                                https://www.ama-assn.org/practice-management/cpt/cpt-evaluation-and-management.\n                                Published December 27, 2023. Accessed January 19, 2024.\n                                2. Commission on Osteopathic College Accreditation. Accreditation of Colleges of\n                                Osteopathic Medicine: COM Continuing Accreditation Standards. American Osteopathic\n                                Association; 2023.\n                                https://osteopathic.org/index.php?aam-media=/wp-content/uploads/COCA-2023-COM-Continuing-Standards.pdf.\n                                3. Goss FR, Blackley SV, Ortega CA, et al. A clinician survey of using speech\n                                recognition for clinical documentation in the electronic health record. Int J Med\n                                Inform. 2019;130:103938.\n                                4. Kauppinen T, Koivikko MP, Ahovuo J. Improvement of report workflow and productivity\n                                using speech recognition--a follow-up study. J Digit Imaging.\n                                2008;21(4):378-382.\n                                5. Radford, A., Kim, J. W., Xu, T., Brockman, G., McLeavey, C., & Sutskever, I.\n                                (2022). Robust Speech Recognition via Large-Scale Weak Supervision. ms, San\n                                Fransisco. \n                                6. Introducing whisper. Introducing Whisper. (n.d.).\n                                https://openai.com/research/whisper",
        "researchers": [
          ": Daniels",
          "T.",
          "Perera",
          "I.",
          "Moriarty",
          "S.",
          "Chotiner",
          "H.",
          "Looney",
          "J.",
          "Gittings",
          "K.",
          "Rawlins II",
          "F."
        ],
        "slug": {
          "current": "ishan-perera"
        },
        "title": "Ishan Perera"
      }
    },
    {
      "operation": "create",
      "documentId": "nrs-scale-demo",
      "data": {
        "_createdAt": "2025-06-04T16:58:32Z",
        "_id": "nrs-scale-demo",
        "_rev": "0R95WGIfgjXsgEpFfwHhvo",
        "_type": "project",
        "_updatedAt": "2025-06-04T16:58:32Z",
        "category": "demo",
        "description": "Interactive Numeric Rating Scale demonstration for medical education",
        "publishedAt": "2025-06-04T16:58:32.474Z",
        "slug": {
          "current": "nrs-scale-demo"
        },
        "title": "NRS Scale Demo"
      }
    }
  ],
  "redirects": [
    {
      "source": "/airway_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/chiari_project1.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/gbcurrent_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/gbnovel_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/ipf_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/ndm_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/pca_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/revive_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/toa_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/vr_project.html",
      "destination": "/projects/ishan-perera",
      "permanent": true
    },
    {
      "source": "/portfolio_scripts.html",
      "destination": "/projects/nrs-scale-demo",
      "permanent": true
    }
  ]
}
